Method for obtaining mitochondria from cells and mitochondria obtained

Through the iMIT method, the problem of functional damage during mitochondrial isolation in the prior art was solved, and a high-functional mitochondrial population was successfully obtained, and the integrity of the inner and outer membranes of the mitochondria and the maintenance of membrane potential was achieved, which was suitable for the treatment of mitochondrial function. Diseases related to disorders.

CN114127263BActive Publication Date: 2024-12-06LUCA SCI INC
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202080052575.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-24
Filing Date
2020-07-22
Publication Date
2024-12-06
Estimated Expiration
2040-07-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively isolate and maintain the functionality of mitochondria from cells, especially maintaining the integrity and membrane potential of their inner and outer membranes, resulting in difficult to resolve diseases related to mitochondrial function.

Method used

Using a method called iMIT (no detergent and homogenate) to reduce the use of surfactant by treating cells in a solution below the critical micelle concentration of surfactant, incubating cells to recover mitochondria, ensuring mitochondria The separation process is free from physical or chemical damage, thereby obtaining a highly functional mitochondrial population.

Benefits of technology

Successfully obtained approximately 60% to 95% of mitochondria remained intact inner and outer membranes, able to maintain membrane potential and functionality in the extracellular environment, and colocalize and fuse with mitochondria in the cell, significantly improving mitochondria stability Sexual and functional.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003479824190000411
    Figure BDA0003479824190000411
  • Figure BDA0003479824190000421
    Figure BDA0003479824190000421
  • Figure BDA0003479824190000481
    Figure BDA0003479824190000481
Patent Text Reader

Abstract

The present disclosure relates to methods of obtaining mitochondria from cells, mitochondria obtained by such methods, and uses of mitochondria obtained by such methods.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority from Japanese Application No. 2019-136283, filed on July 24, 2019, the entire contents of which are incorporated herein by reference. Background Art

[0003] Mitochondria are organelles that play three major roles: 1) metabolism, such as ATP synthesis; 2) intracellular signaling, such as Ca2+ and reactive oxygen species; and 3) control of cell death, such as apoptosis and necrosis. In this sense, mitochondria are closely related to diseases and have been studied by many researchers from a health perspective.

[0004] For mitochondrial function, the folded inner membrane and the surrounding outer membrane and the electron transport system located in the inner membrane play a key role. The inner membrane forms a highly folded structure called cristae, which is believed to hold the supercomplex of the electron transport system in the cristae membrane and maintain a high proton concentration by trapping pumping protons in the cristae space. The electrochemical proton gradient formed by the electron transport system enables the transport of anions and the synthesis of ATP and the transport of cations.

[0005] Decreased mitochondrial function can lead to a variety of different diseases. Currently there is no known method in the art to isolate mitochondria from cells in a manner that preserves mitochondrial function and structural integrity. The present disclosure is intended to address this and other needs. Summary of the invention

[0006] The present disclosure provides a population of mitochondria isolated or obtained or processed, wherein the mitochondria in the population exhibit superior functional capabilities. For example, on the one hand, the present disclosure provides a population of isolated mitochondria, wherein at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the mitochondria in the population have complete inner and outer membranes; and / or at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the mitochondria in the population are polarized when measured by a fluorescent indicator. In an embodiment, the fluorescent indicator is selected from positively charged dyes such as JC-1, tetramethylrhodamine methyl ester (TMRM) and tetramethylrhodamine ethyl ester (TMRE).

[0007] In embodiments, the present disclosure provides a population of isolated mitochondria, wherein at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the mitochondria in the population maintain functional capacity (e.g., polarized) in the extracellular environment. In embodiments, the functional capacity in the extracellular environment is measured by a fluorescent indicator of membrane potential. In embodiments, the fluorescent indicator is selected from positively charged dyes such as JC-1, TMRM and TMRE. In embodiments, the extracellular environment may include a total calcium concentration of about 4 mg / dL to about 12 mg / dL or about 1 mmol / L (1000 μM) to about 3 mmol / L (3000 μM). For example, in embodiments, the extracellular environment includes a total calcium concentration of about 8 mg / dL to about 12 mg / dL or about 2 mmol / L (2000 μM) to about 3 mmol / L (3000 μM). In embodiments, the extracellular environment comprises a free or active calcium concentration of about 4 mg / dL to about 6 mg / dL or about 1 mmol / L (1000 μM) to about 1.5 mmol / L (1500 μM). In embodiments, the mitochondrial population maintains functional capacity in an environment having a higher calcium concentration than the calcium environment in the cell.

[0008] In embodiments, provided herein is an isolated population of mitochondria, wherein at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population are not undergoing dynamin-related protein 1 (drp1)-dependent fission. In embodiments, provided herein is an isolated population of mitochondria, wherein the mitochondria have an inner membrane and an outer membrane, wherein the inner membrane of the mitochondria comprises densely folded cristae.

[0009] In embodiments, provided herein is a population of isolated mitochondria, wherein at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population have a substantially non-filamentous, non-branched structure or shape. For example, in embodiments, the mitochondria provided herein are round, dot-shaped, spherical, irregularly shaped, and / or slightly elongated when viewed under a microscope, or any mixture thereof. In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population have a major diameter to minor diameter ratio of no more than 4:1, no more than 3.5:1, or no more than 3:1. In embodiments, in the mitochondrial population provided herein, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the separated mitochondria have a length shorter than two or three times the hydrodynamic diameter of the mitochondria. In this way, the separated mitochondria provided herein have a shape (non-filamentous) significantly different from the shape (filamentous) of most mitochondria in the cell. Therefore, in embodiments, the mitochondrial population provided herein has a shape different from the mitochondria present in the cell and not yet separated, wherein the shape of at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the mitochondria in the population is non-filamentous. In embodiments, the separated mitochondrial population provided herein shows a reduced binding to mitochondrial associated membrane (MAM). In embodiments, the binding to MAM is measured by the expression of glucose-regulated protein 75 (GRP75). In embodiments, the isolated mitochondrial populations provided herein exhibit about 60%, at least about 65%, at least about 70%, about 60%, about 50%, about 40%, about 30% or less binding to MAMs compared to mitochondria in cells and / or mitochondria obtained by conventional isolation methods, such as those further described herein involving homogenization and / or high levels of detergents. In embodiments, the isolated mitochondrial populations provided herein exhibit reduced binding to MAMs, wherein the reduction is at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70% or more relative to mitochondria in cells or mitochondria obtained by conventional isolation methods.

[0010] In embodiments, the size of the isolated mitochondrial population provided herein is between about 500 nm and about 3500 nm. In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% of the mitochondria in the population are between about 500 nm and about 3500 nm. In embodiments, the average size of mitochondria in the population is about 500 nm, about 600 nm, about 700 nm, about 800 nm, about 900 nm, about 1000 nm, about 1100 nm, about 1200 nm, about 1300 nm, about 1400 nm, about 1500 nm, about 1600 nm, about 1700 nm, about 1800 nm, about 1900 nm, about 2000 nm, about 2100 nm, about 2200 nm, about 2300 nm, about 2400 nm, about 2500 nm, about 2600 nm, about 2700 nm, about 2800 nm, about 2900 nm, about 3000 nm, about 3100 nm, about 3200 nm, about 3300 nm, about 3400 nm, or about 3500 nm. In embodiments, the polydispersity index (PDI) of the isolated mitochondrial population is from about 0.2 to about 0.8. In embodiments, the PDI of the isolated mitochondrial population is from about 0.2 to about 0.5. In embodiments, the PDI of the isolated mitochondrial population is from about 0.25 to about 0.35. In embodiments, the zeta potential of the mitochondrial population is from about -15 mV to about -40 mV. In embodiments, the zeta potential of the mitochondrial population is about -20 mV, about -25 mV, about -30 mV, about -35 mV, or about -40 mV.

[0011] In an embodiment, when the isolated mitochondrial population provided herein is contacted with a cell population, the isolated mitochondrial population can be incorporated into the cell and / or co-localized with the endogenous mitochondria in the cell. For example, in an embodiment, the present disclosure provides a method of obtaining mitochondria from a cell and subsequently contacting a cell population (e.g., in vitro or in vivo cells) with the isolated mitochondrial population. In such embodiments, the mitochondria isolated by the iMIT method described herein provided herein can co-localize with the endogenous mitochondria present in the cell. In an embodiment, the mitochondria provided herein can also fuse with the mitochondria present in the cell they contact. In an embodiment, a significant portion of the isolated mitochondrial population can co-localize and / or fuse with the endogenous mitochondria in the cell. For example, in an embodiment, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% of the mitochondria in the population can co-localize and / or fuse with the endogenous mitochondria in the cell. Thus, the mitochondria provided herein differ significantly from mitochondria isolated by conventional methods in that they are able to co-localize and / or fuse with endogenous mitochondria in cells.

[0012] In embodiments, the isolated mitochondria provided herein are stable and / or polarized after storage at about 4°C, and / or maintain membrane potential and / or maintain an intact inner and outer membrane and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). For example, in embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population are stable and / or polarized after storage at about 4°C, and / or maintain membrane potential and / or maintain an intact inner and outer membrane and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). In embodiments, the isolated mitochondria provided herein are stable and / or polarized after storage at about -20°C or lower, and / or maintain membrane potential and / or maintain an intact inner and outer membrane and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). For example, in embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population are stable and / or polarized after storage at about -20°C, and / or maintain membrane potential and / or maintain an intact inner and outer membrane and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). In embodiments, the isolated mitochondria provided herein are stable and / or polarized after storage at about -80°C or lower, and / or maintain membrane potential and / or maintain an intact inner and outer membrane and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). For example, in embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population are stable and / or polarized after storage at about -80°C, and / or maintain membrane potential and / or maintain an intact inner and outer membrane and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). In embodiments, the isolated mitochondria provided herein are stable and / or polarized after storage in liquid nitrogen and / or maintain membrane potential and / or maintain intact inner and outer membranes and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL).For example, in embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population are stable and / or polarized after storage in liquid nitrogen, and / or maintain membrane potential and / or maintain intact inner and outer membranes and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). In embodiments, the storage lasts at least about 2 hours, at least about 6 hours, at least about 12 hours, at least about 24 hours, at least about 48 hours, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, or longer. Therefore, in embodiments, the significant difference between the isolated mitochondria provided herein and the mitochondria isolated by conventional methods is at least that they maintain functional capacity after fresh isolation and even storage.

[0013] In embodiments, the isolated mitochondria provided herein are stable and / or polarized after the mitochondrial population has been frozen and stored and then thawed, and / or after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL), the membrane potential is maintained and / or the inner and outer membranes are maintained intact and / or the ability to function is maintained. In embodiments, after being frozen and then thawed, the membrane potential is maintained at a rate of about 90% relative to the membrane potential of the mitochondria before freezing. For example, in embodiments, the polarizability of the mitochondrial population that has been frozen and thawed is about 90% of the polarizability of the population before freezing. In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population are stable and / or polarized after being frozen and then thawed, for example, after being frozen and then thawed 1, 2, 3, or more times, and / or maintain membrane potential and / or maintain intact inner and outer membranes and / or maintain the ability to function after exposure to the extracellular environment (e.g., after exposure to a total calcium concentration of about 4 mg / dL to about 12 mg / dL). Thus, in embodiments, the isolated mitochondria provided herein differ significantly from mitochondria isolated by conventional methods in that they maintain functional capacity even after being frozen and then thawed.

[0014] In embodiments, the isolated mitochondrial populations provided herein can be incorporated into cells and / or co-localized and / or fused with endogenous mitochondria in cells after the mitochondria are stored at any temperature provided herein (e.g., 4°C ± 3°C, -20°C ± 3°C, -80°C ± 3°C, or in liquid nitrogen). For example, in embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the mitochondria in the population can be incorporated into cells and / or co-localized and / or fused with endogenous mitochondria in cells after the mitochondria have been stored and / or have undergone one or more freeze-thaw cycles. In an embodiment, the method of storing and thawing the isolated mitochondrial population provided herein comprises storing the population at about -20°C ± 3°C, about -80°C ± 3°C or lower (e.g., in liquid nitrogen), and then thawing the mitochondria at about 20°C ± 3°C or lower, wherein the mitochondria melt in about 5 minutes, about 4 minutes, about 3 minutes, about 2 minutes, or about 1 minute. In a specific embodiment, the mitochondrial population melts in about 1 minute. Therefore, in an embodiment, the significant difference between the mitochondria provided herein and the mitochondria isolated by conventional methods is at least that they can be incorporated into cells and / or co-localized and / or fused with endogenous mitochondria in cells, while the mitochondria isolated by conventional methods cannot be incorporated into cells and / or co-localized and / or fused with endogenous mitochondria in cells, or the ability to exhibit such behavior is greatly reduced. In an embodiment, the co-localized isolated mitochondria can form filamentous structures, network structures, and / or reticular structures.

[0015] In embodiments, the present disclosure provides a composition comprising the isolated mitochondria provided herein. In embodiments, the composition further comprises one or more pharmaceutically acceptable carriers.

[0016] In an embodiment, the present disclosure provides a method for isolating mitochondria from cells, which is different from conventionally known methods and produces mitochondria with superior functions and other characteristics provided herein. In an embodiment, the method for isolating mitochondria from cells comprises: treating the cells in a first solution containing a surfactant, wherein the concentration of the surfactant in the first solution is lower than the critical micelle concentration (CMC) of the surfactant; removing the surfactant to form a second solution; incubating the cells in the second solution; and recovering mitochondria from the second solution. In an embodiment, the concentration of the surfactant in the first solution is about 50% or less of the CMC of the surfactant. For example, in an embodiment, the concentration of the surfactant in the first solution is about 40% or less, about 30% or less, about 20% or less, or about 10% or less of the CMC of the surfactant.

[0017] In an embodiment, the surfactant is a nonionic surfactant. In an embodiment, the surfactant is selected from Triton-X 100, Triton-X 114, Nonidet P-40, n-dodecyl-D-maltoside, Tween-20, Tween-80, saponin and digitonin. In an embodiment, the surfactant is saponin or digitonin. In an embodiment, the concentration of the surfactant is less than about 400 μM. For example, in an embodiment, the concentration of the surfactant in the first solution is less than about 300 μM, less than about 200 μM, less than about 100 μM or less than about 50 μM. In an embodiment, the concentration of the surfactant in the first solution is about 100 μM, about 75 μM, about 60 μM, about 50 μM, about 40 μM, about 30 μM or about 20 μM. In an embodiment, the concentration of the surfactant in the first solution is about 20 μM to about 50 μM or about 30 μM to about 40 μM.

[0018] In an embodiment, the first solution further comprises a buffer comprising one or more of a tonicity agent, an osmotic pressure modifier, or a chelating agent. In an embodiment, the first solution comprises tris buffer, sucrose, and a chelating agent.

[0019] In embodiments, the step of treating the cells in a first solution containing a low concentration of surfactant (e.g., less than the CMC of the surfactant) comprises incubating the cells in the first solution at room temperature for about 2 minutes to about 30 minutes. For example, in embodiments, the step of treating the cells in the first solution comprises incubating the cells in the first solution for about 2, about 5, about 10, about 15, about 20, about 25, or about 30 minutes. The incubation can be performed at a temperature of about 4°C to about 37°C.

[0020] In embodiments, the step of removing the surfactant comprises reducing the surfactant in the solution to less than 10% of the concentration of the surfactant in the first solution, or less than 1% of the concentration of the surfactant in the first solution. In embodiments, the step of removing the surfactant comprises washing the cells with a buffer.

[0021] In embodiments, the step of incubating with the second solution comprises incubating the cells in the second solution for about 5 minutes to about 30 minutes. For example, in embodiments, the step of incubating the cells in the second solution comprises incubating the cells in the second solution for about 5, about 10, about 15, about 20, about 25, or about 30 minutes. In embodiments, the step of incubating the cells in the second solution is performed at a temperature of about 4°C ± 3°C or on ice.

[0022] In an embodiment, the step of recovering mitochondria from the second solution comprises collecting a supernatant to recover the isolated mitochondria. In an embodiment, the step of recovering mitochondria from the second solution comprises centrifuging the second solution and collecting a supernatant after centrifugation to recover the isolated mitochondria.

[0023] In embodiments, the iMIT may be performed on cells attached to a culture surface. In embodiments, the iMIT may be performed on cells attached to a culture surface without separating the cells from the surface. In embodiments, the step of recovering mitochondria from the second solution comprises collecting a supernatant to recover the separated mitochondria, after which the remaining cells on the culture surface may optionally be washed with the second solution or another second solution to combine them with the supernatant.

[0024] In embodiments, the methods provided herein further comprise freezing the isolated mitochondria. In embodiments, the method comprises freezing the mitochondria in a buffer comprising a cryoprotectant (e.g., glycerol). In embodiments, the method comprises freezing the mitochondria in the buffer in liquid nitrogen. In embodiments, the method further comprises thawing the mitochondria after freezing. In embodiments, the method of thawing mitochondria comprises thawing the mitochondria rapidly, for example, within about 5 minutes or within about 1 minute. In embodiments, the mitochondria are melted in a warm bath having a temperature of about 20°C ± 3°C to about 37°C ± 3°C. In embodiments, the mitochondria are melted at about 20°C ± 3°C or lower.

[0025] In an embodiment, the present disclosure provides an isolated mitochondrial population obtained by a method provided herein. In an embodiment, the method provided herein is an "iMIT" method, and the mitochondria obtained by this method are referred to herein as "Q" mitochondria. In an embodiment, the present disclosure provides a composition and / or formulation comprising an isolated mitochondrial population obtained by a method provided herein.

[0026] In an embodiment, the present disclosure provides a method for treating or preventing a disease or disorder associated with mitochondrial dysfunction, the method comprising contacting a subject's cells with an isolated mitochondrial population, such as Q mitochondria, provided herein. In an embodiment, the disease or disorder is an ischemia-related disease or disorder. For example, in an embodiment, the ischemia-related disease or disorder is selected from cerebral ischemia-reperfusion, hypoxic-ischemic encephalopathy, acute coronary syndrome, myocardial infarction, liver ischemia-reperfusion injury, ischemic injury compartment syndrome, vascular occlusion, wound healing, spinal cord injury, sickle cell disease, and transplant organ reperfusion injury. In an embodiment, the disease or disorder is a genetic disorder. In an embodiment, the disease or disorder is cancer, cardiovascular disease, eye disorder, ear disorder, autoimmune disease, inflammatory disease, or fibrotic disorder. In an embodiment, the disease is acute respiratory distress syndrome (ARDS). In an embodiment, the disease or disorder is an aging disease or disorder or a condition associated with aging. In an embodiment, the disease or disorder is preeclampsia or intrauterine growth restriction (IUGR).

[0027] In embodiments, the present disclosure provides methods for treating or preventing a disease or disorder provided herein, wherein the method comprises administering the isolated mitochondrial population or the composition to a subject in need thereof. In embodiments, the administration route of the isolated mitochondria is by intravenous, intraarterial, intratracheal, subcutaneous, intramuscular, inhalation or intrapulmonary administration. In embodiments, the subject is a mammal, such as a human.

[0028] In an embodiment, the present disclosure provides a kind of mitochondria with complete inner membrane and outer membrane, wherein the inner membrane comprises folded cristae, wherein the mitochondria have been separated from cells, wherein the mitochondria are polarized when measured by a fluorescent indicator (e.g., JC-1, TMRM or TMRE), and wherein the mitochondria are capable of maintaining polarization in an extracellular environment. In an embodiment, the folded cristae are densely folded cristae. In an embodiment, the mitochondria have a substantially non-filamentous shape. In an embodiment, the mitochondria comprise a voltage-dependent anion channel (VDAC) bound to tubulin on its surface. For example, in an embodiment, the mitochondria separated comprise dimeric tubulin bound to VDAC on its surface. In an embodiment, the tubulin comprises at least α-tubulin. In an embodiment, the tubulin is a heterodimer comprising α-tubulin and β-tubulin. In an embodiment, the tubulin is a homodimer. In an embodiment, when measured by GRP75 expression, the separated mitochondria exhibit a reduction in binding to MAM. For example, in embodiments, the isolated mitochondria exhibit about 70%, about 60%, about 50%, about 40%, about 30% or less binding to MAMs compared to mitochondria present in cells (i.e., not yet isolated) and / or mitochondria isolated by conventional isolation methods, such as those further described herein involving homogenization and / or high levels of detergents. In embodiments, the isolated mitochondria provided herein exhibit a reduction in binding to MAMs, wherein the reduction is at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70% or more relative to mitochondria present in cells (i.e., not yet isolated) and / or mitochondria isolated by conventional isolation methods.

[0029] In embodiments, the isolated mitochondria provided herein have a membrane potential between about -30mV and about -220mV. In embodiments, the isolated mitochondria are non-filamentous in shape. In embodiments, the isolated mitochondria are not undergoing drp1-dependent fission. In embodiments, the size of the isolated mitochondria is between about 500nm and 3500nm. For example, in embodiments, the size of the isolated mitochondria is about 500, about 600, about 700, about 800nm, about 900nm, about 1000nm, about 1100nm, about 1200nm, about 1500nm, about 2000nm, about 2500nm, about 3000nm or about 3500nm.

[0030] In embodiments, the present disclosure provides an isolated mitochondria obtained by a method provided herein. In embodiments, the present disclosure provides compositions and preparations comprising the isolated mitochondria provided herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1A The distribution of the fluorescence intensity ratio of the fluorescent indicator of mitochondria depolarized with a depolarizing agent (the ratio of the mitochondrial fluorescence intensity to the background fluorescence intensity) is shown. Figure 1A In this experiment, 97.5% of depolarized mitochondria showed a fluorescence intensity lower than 1.2. Therefore, in this experiment, mitochondria were considered to have membrane potential when the fluorescence intensity ratio exceeded 1.2.

[0032] Figure 1B A microscopic image of mitochondria obtained by the method of the present invention using transmitted light and a fluorescent image obtained using a fluorescent indicator (TMRE) in the same area as the transmitted light image are shown. The scale bar represents 10 μm.

[0033] Figure 2A Comparison of TMRE fluorescence images of mitochondria obtained by the DHF method and TMRE fluorescence images of mitochondria obtained by the homogenization method is shown. The scale bar represents 25 μm.

[0034] Figure 2B The upper panel shows the protein content (μg) of the mitochondrial fraction isolated by the DHF method compared to the homogenization method. Figure 2B The lower graph shows TMRE positive mitochondria (%) of mitochondrial fractions isolated by the DHF method compared to the homogenization method. The DHF method yielded a statistically significantly higher % of TMRE positive fractions (p<0.05).

[0035] Figure 2C Shown are a microscopic image of isolated mitochondria (upper panel) and a fluorescent image of TMRE staining (lower left panel). The images are merged in the lower right panel and show that almost all mitochondria in the isolated population are polarized.

[0036] Figure 2D Electron microscopic images of mitochondria isolated by the methods provided herein are shown. The scale bar is 1 μm. The images show that the isolated mitochondria have intact inner and outer membranes and densely folded cristae.

[0037] Figure 2E STED microscopic images of Q mitochondria, H mitochondria (mitochondria isolated by conventional homogenization methods) and D mitochondria (mitochondria isolated by conventional detergent methods) are shown. The outer membrane of mitochondria is stained green (immunofluorescence of Tom20), and the inner membrane is stained red with Mitotracker Red. The ratio of the intact outer membrane and the quantitative size of the isolated mitochondria are provided in Table 3.

[0038] Figure 3AShown are the size distribution, polydispersity (PDI) and measured zeta potential of the mitochondrial population obtained by dynamic light scattering before freeze-thaw for mitochondrial extraction without homogenization or without surfactant at a concentration above the critical micelle concentration (DHF method) in the Examples.

[0039] Figure 3B Shown are the size distribution, polydispersity (PDI) and measured zeta potential of the mitochondrial population obtained by the DHF method after freeze-thaw, obtained by dynamic light scattering.

[0040] Figure 3C Shown are the size distribution, polydispersity (PDI) and measured zeta potential of the mitochondrial population after freeze-thaw obtained by the same method as the DHF method except that the centrifugation procedure in the DHF method was performed at 1000×g (entry 7 in 2.2.1).

[0041] Figure 3D Shown are superimposed images of transmission microscopy images of mitochondrial populations before and after freezing and thawing and TMRE staining images obtained by the DHF method.

[0042] Figure 4 Shown are the mitochondrial populations isolated from each mouse tissue by the DHF method, as well as the size distribution, polydispersity (PDI), and measured zeta potential of the isolated mitochondrial populations obtained by dynamic light scattering.

[0043] Figure 5A Shown are changes in TMRE fluorescence intensity over time (minutes) in single mitochondria isolated by the iMIT method and treated with 1 mM malate and 1 μM oligomycin at the indicated time points.

[0044] Figure 5B Figure 2 shows TMRE fluorescence images of single mitochondria isolated by the iMIT method over a typical time course. Figure 5A Malate was added at the time points indicated in (1 mM malate between 0 and 1 min and 1 μM oligomycin between 5 and 6 min).

[0045] Fig. 6A Isolated mitochondria (middle panel) are shown co-localized with mitochondria in recipient fibroblasts (left panel). The merged image is shown in the right panel.

[0046] Figure 6B Co-localization of Q mitochondria with mitochondria in recipient cells is also shown (lower panel). In contrast, mitochondria isolated by the homogenization method appeared to be inside the recipient cells but did not co-localize with endogenous mitochondria.

[0047] Fig. 7AShown are fixed cells stained to show the shape of mitochondria in the absence (left) or presence (right) of 10 μM Drp1 inhibitor Mdivi1. Mitochondria in cells maintained a network-like branching shape regardless of the presence of 10 μM Mdivi1.

[0048] Figure 7B It is shown that after addition of 30 μM digitonin and subsequent washing steps, the shape of mitochondria in cells is non-filamentous, regardless of the presence or absence of 10 μM Mdivi1.

[0049] Figure 7C It is shown that GFP+ mitochondria isolated by iMIT from cells treated with 0 or 10 μM Mdivi1 retained a non-filamentous shape.

[0050] Figure 8 A comparison of polarization between Q mitochondria (upper panel) and mitochondria isolated by a conventional detergent method (middle panel) or a conventional homogenization method (lower panel) is shown. The left column of the figure is a microscopic image and shows that mitochondria were isolated by various methods. The right panel shows TMRE fluorescence and indicates that only Q mitochondria have a high proportion of polarized mitochondria.

[0051] Fig.9A Calcein fluorescence staining is shown, indicating that Q mitochondria have intact mitochondrial membranes after isolation (upper panel) and maintain intact membranes even after addition of 0.96 mM calcium (lower panel).

[0052] Fig. 9B TMRE fluorescence staining is shown, indicating that Q mitochondria are polarized before (upper panel) and after (lower panel) exposure to calcium.

[0053] Fig. 10A It was shown that physical disruption of the mitochondrial population disrupted the mitochondrial membrane, and the addition of 0.96 mM calcium further disrupted the membrane such that calcein fluorescence could no longer be detected after the combination of agitation and a high calcium environment.

[0054] Fig. 10B It is shown that membrane potential (measured by TMRE staining) is maintained after physical disruption of mitochondria by agitation, but then disappears after addition of 0.96 mM calcium.

[0055] Fig.11 The GRP75 protein content obtained by western blot determination is shown in iMIT mitochondria (Q mitochondria; right lane) compared with mitochondria isolated by conventional detergent method (D, left lane) or conventional homogenization method (H, middle lane) (left panel). Cytochrome oxidase was used as a protein content control (right panel).

[0056] Fig.12 A schematic diagram of the study design for the 4-week myocardial infarction model study is provided.

[0057] Fig.13 Left ventricular contractile function in rats in the ischemia-reperfusion model is shown. EF% of animals in the sham, PBS, homogenized mitochondria, and high and low Q mitochondria groups are shown. **(p<0.01).

[0058] Fig.14 A schematic diagram of the study design for the 7-day myocardial infarction model study is provided.

[0059] Fig.15 Shown are the ejection fractions (EF%) at 1, 3, and 7 days after administration with PBS or mitochondria (Q) in the test group (IR Q), negative control (IR PBS), or sham infarction (Sham Q) groups. DETAILED DESCRIPTION

[0060] The present disclosure provides highly functional mitochondria and highly functional mitochondrial populations that can be used to treat a variety of different diseases, disorders and conditions. In embodiments, the mitochondria have been isolated from cells and retain the ability to function. For example, in embodiments, the mitochondria provided herein have been isolated from cells and retain a high degree of polarization and / or other aspects of mitochondrial function described herein. The present disclosure also provides methods for obtaining mitochondria, which methods make the obtained mitochondria highly functional. The methods and isolated mitochondria provided herein are significantly improved over previously known methods for isolating mitochondria from cells and isolated mitochondria obtained from those previously known methods.

[0061] When used in this article, the term "isolation" refers to collecting mitochondria from the inside of the cell to the outside of the cell. The term "isolation" can include removing at least one other component in the solution from the solution containing mitochondria collected outside the cell. Therefore, when used in this article, the term "isolated" means mitochondria that are no longer in the cell. The terms "processed" or "obtained" and the like can be used interchangeably with "isolated". In an embodiment, isolated mitochondria or isolated mitochondrial populations have been processed by the methods provided herein to obtain it from the cellular environment. The method provided herein is a means of obtaining mitochondria from cells in a manner that causes minimal structural damage to the mitochondria and allows them to maintain membrane integrity and membrane potential even after separation.

[0062] When used herein, the term "cell" is a eukaryotic cell, i.e., a cell containing mitochondria in the cytoplasm, such as an animal cell such as a mammalian cell, preferably a human cell. When used herein, the term "cell" includes cells present in a tissue, cells separated from a tissue (e.g., a single cell), and cells within a cell population (e.g., a cell population obtained from a subject's tissue and / or a cell population obtained from a cell line).

[0063] When used in this article, the term "mitochondria" is a kind of organelle present in eukaryotic cells, which has a double lipid membrane, i.e., an inner membrane and an outer membrane, and a matrix surrounded by cristae and inner membrane. Mitochondria (more than one mitochondria) have enzymes on their inner membranes, such as the respiratory chain complexes involved in oxidative phosphorylation. Due to the internal-external proton gradient formed by the effect of the respiratory chain complexes, the inner membrane has a membrane potential. It is believed that mitochondria can not maintain membrane potential when the inner membrane is destroyed. Known mitochondria have their own genome (mitochondrial genome), which is different from the genome in the nucleus. When used in this article, a "mitochondrial colony" is a colony comprising multiple mitochondria.

[0064] When used in this article, the term "polarization" means that the mitochondria exhibit membrane potential. When used in this article, the term "polarization rate" is the ratio of polarized mitochondria to total mitochondria. Mitochondrial polarization can be easily detected, for example, by those skilled in the art through commercially available fluorescent indicators. Fluorescent indicators include but are not limited to JC-1, tetramethylrhodamine methyl ester (TMRM) and tetramethylrhodamine ethyl ester (TMRE).

[0065] As used herein, the term "surfactant" means a molecule having a hydrophilic component and a hydrophobic component in one molecule. Surfactants have the effect of reducing the surface tension at the interface or mixing polar and non-polar substances by forming micelles. Surfactants are roughly divided into nonionic surfactants and ionic surfactants. Nonionic surfactants are surfactants in which the hydrophilic component is not ionized, and ionic surfactants are surfactants in which the hydrophilic component contains cations or anions or both cations and anions.

[0066] As used herein, the term "critical micelle concentration" (CMC) refers to a concentration at which the surfactant forms micelles and further surfactant added to the system contributes to micelle formation, particularly bulk concentrations. At concentrations above the critical micelle concentration, adding surfactant to the system ideally increases the amount of micelles, particularly the number of micelles.

[0067] Conventional methods for isolating mitochondria include mechanical grinding (homogenization) of intact cells or methods of collecting mitochondria from cells by dissolving cell membranes using surfactants or detergents. In the latter method, the surfactant or detergent is applied to the cells at a concentration high enough to destroy the cell membrane and any membranes within the cell (i.e., at a concentration higher than the CMC). In some cases, these methods (homogenization and use of high concentrations of surfactants or detergents) have been used in combination to increase the yield of mitochondria. Other methods include methods involving freeze-thaw to destroy cell membranes and / or ultrasonic treatment. The mitochondria obtained by these methods may exhibit some functions, but considering the low polarization rate obtained by these methods, it is believed that (1) in the method of homogenizing cells and / or freezing and thawing cells and / or ultrasonic treatment of cells to destroy cell membranes, the mitochondria forming a network structure within the cell are physically damaged by shear stress and / or ice crystal formation and / or ultrasonic waves that damage the membrane, respectively; and (2) in the surfactant-based method, the mitochondrial membrane is exposed to a surfactant, which can dissolve the mitochondrial membrane as well as the cell membrane, or the surfactant binds to mitochondrial membrane proteins, and then the isolated mitochondria are chemically damaged by the surfactant.

[0068] Researchers have also tried to collect mitochondria by using proteins instead of surfactants to make holes in the plasma membrane. (1) This method also produced some high-quality mitochondria, but the yield was low and most mitochondria were damaged. To increase the yield, cells were repeatedly pipetted and the mitochondria outside the cells appeared damaged.

[0069] On the one hand, the present disclosure provides mitochondria isolated by a new method, which is referred to herein as the "detergent-free and homogenized (DHF)" method or the "iMIT" method. As described herein, mitochondria isolated by the iMIT method are not damaged (e.g., retain inner and outer membrane integrity) and maintain functional capabilities (e.g., membrane potential). The mitochondria obtained by the iMIT method are referred to herein as "Q" mitochondria. These mitochondria are suitable for treating a variety of diseases and disorders, including the diseases and disorders described herein, by, for example, mitochondrial transplantation. Mitochondrial transplantation is a treatment that is expected to be useful in a variety of diseases and disorders. Exogenous mitochondria (e.g., Q mitochondria) are internalized into cells with severe mitochondrial dysfunction and / or cells in which the influx of highly functional mitochondria is beneficial, to restore and / or enhance mitochondrial function.

[0070] Another application envisioned herein is to study mitochondrial mechanisms, particularly the response of mitochondria to stimulation. Isolation of mitochondria is very suitable for studying how mitochondria react to intracellular signals due to the controllability of their surroundings (for example, the proof of Peter Mitchell's chemical osmotic theory can be carried out in isolated mitochondria, and the theory believes that the proton driving force is responsible for driving the synthesis of ATP, i.e., when electrons advance through the electron transport chain, protons are pumped through the mitochondrial inner membrane). Considering the polarizability of the mitochondria obtained by the current method, it is believed that the isolation of mitochondria obtained by conventional methods suffers from severe damage to both outer membrane and inner membrane. Therefore, by using conventional methods to collect a large number of mitochondria, it is believed that only a small number of residual functions can be measured. In contrast, the mitochondria obtained by the disclosed method can measure many phenomena that cannot be measured in damaged mitochondria.

[0071] The pollution of damaged mitochondria may cause adverse effects to living organisms and cells. The mitochondria provided herein are superior to the mitochondria separated by conventional methods, in part because they are not accompanied by cytotoxicity or are accompanied by far lower cytotoxicity than the mitochondria separated by conventional methods, for example. In addition, the mitochondria provided herein are superior to the mitochondria separated by conventional methods because they are superior in terms of the functional capabilities described in this article. In the method disclosed herein, it is expected that the degree of damage can be reduced, because the mitochondria are not affected by physical destruction or chemical destruction of surfactants during their collection, and are not contacted with surfactants or with surfactants at concentrations far below CMC that cannot be removed from the first solution but will not damage mitochondria during the collection of iMIT, and it is expected that the degree of damage can be minimized, particularly if they are not in contact with surfactants, so it is expected that the adverse effects of damaged mitochondria on organisms and cells can be reduced.

[0072] Methods for obtaining mitochondria

[0073] In an embodiment, the present disclosure provides a method for recovering or isolating mitochondria from cells, the method comprising: treating cells in a solution containing a surfactant at a concentration below the critical micelle concentration (CMC), removing the surfactant from the solution containing the treated cells, and then incubating the surfactant-treated cells to recover the mitochondria in the solution, thereby recovering the mitochondria from the cells. The method is referred to herein as "iMIT". Therefore, iMIT, a method for obtaining mitochondria from cells, is provided herein, the method comprising:

[0074] (A) treating cells in a first solution with a surfactant at a concentration below the critical micelle concentration (CMC),

[0075] (B) removing the surfactant from the first solution to form a second solution, and

[0076] (C) incubating the surfactant-treated cells in the second solution to recover the mitochondria in the second solution. The above (A) to (C) and additional configurations of the method are described below.

[0077] According to the methods of the present disclosure, cells having mitochondria in the cytoplasm are treated in a solution with a surfactant at a concentration below the critical micelle concentration. Thus, in embodiments, the cell membrane is weakened in structural strength but is not permeabilized due to the low concentration of the surfactant, while the mitochondrial membrane is exposed to little or no exposure to the surfactant and remains intact. In embodiments, the cell membrane may be partially permeabilized, but the mitochondrial membrane is exposed to little or no exposure to the surfactant due to the low concentration of the surfactant and remains intact.

[0078] In embodiments, the solution of (A) may include a buffer. Exemplary buffers for methods provided herein include, for example, Tris buffers, HEPES buffers, and phosphate buffers. Buffers may, for example, have a pH of 6.7-7.6 (e.g., pH 6.8-7.4, pH 7.0-7.4, e.g., pH 7.2-7.4, e.g., pH 7.4). In embodiments, the buffer may include a tonicity agent and an osmotic pressure modifier. Exemplary tonicity agents and osmotic pressure modifiers include monosaccharides (e.g., glucose, galactose, mannose, fructose, inositol, ribose, xylose, etc.), disaccharides (e.g., lactose, sucrose, cellobiose, trehalose, maltose, etc.), trisaccharides (e.g., raffinose, melesinose, etc.), polysaccharides (e.g., cyclodextrins, etc.), sugar alcohols (e.g., erythritol, xylitol, sorbitol, mannitol, maltitol, etc.), glycerol, diglycerol, polyglycerol, propylene glycol, polypropylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, etc. The buffer may also contain a chelating agent, particularly a chelating agent for divalent metals such as a chelating agent for calcium ions. Chelating agents include, for example, ethylene glycol ether diaminetetraacetic acid (EGTA) and ethylenediaminetetraacetic acid (EDTA).

[0079] In embodiments, the buffer may be a Tris buffer comprising sucrose and a chelating agent, wherein the pH is 6.7-7.6 (e.g., pH 6.8-7.4, pH 7.0-7.4, e.g., pH 7.2-7.4, e.g., pH 7.4). In embodiments, the Tris buffer may comprise digitonin or saponin or another surfactant provided herein. In embodiments, the digitonin or saponin or other surfactant may have a concentration of 20% or less, 15% or less, 14% or less, 13% or less, 12% or less, 11% or less, or 10% or less of the critical micelle concentration. In embodiments, digitonin can be used at a concentration of 400 μM or less, 350 μM or less, 200 μM or less, 150 μM or less, 100 μM or less, 90 μM or less, 80 μM or less, 70 μM or less, 60 μM or less, 50 μM or less, 40 μM or less or 30 μM or less (e.g., a concentration of 30 μM). In embodiments, saponin can be used at a concentration of 400 μM or less, 400 μM or less, 350 μM or less, 200 μM or less, 150 μM or less, 100 μM or less, 90 μM or less, 80 μM or less, 70 μM or less, 60 μM or less, 50 μM or less, 40 μM or less or 30 μM or less (e.g., a concentration of 30 μM).

[0080] In an embodiment, the surfactant used in the method provided herein can be an ionic or nonionic surfactant. The nonionic surfactant used in the present invention can include, for example, the form of esters, ethers and alkyl glycosides. Nonionic surfactants include, for example, alkyl polyethylene glycols, polyoxyethylene alkylphenyl ethers and alkyl glycosides. Nonionic surfactants can include Triton-X 100, Triton-X 114, Nonidet P-40, n-dodecyl-D-maltoside, Tween-20, Tween-80, saponin and / or digitonin. In the treatment step (A), at least one of the surfactants selected from Triton-X 100, saponin and digitonin is used. In an embodiment, the surfactant is saponin or digitonin.

[0081] In an embodiment, the treatment step (A) comprises treating the cells with a surfactant at a concentration below the critical micelle concentration. The treatment time of the cells in the step (A) can be, for example, 1-30 minutes, such as 1-10 minutes, or, for example, 1-5 minutes, such as 2-4 minutes, such as 3 minutes. The treatment of the cells in (A) can be carried out on ice, at 4°C or room temperature, or at a temperature therebetween.

[0082] In an embodiment, the concentration of the surfactant in the treatment step (A) can be a concentration below the critical micelle concentration, such as 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 15% or less, 14% or less, 13% or less, 12% or less, 11% or less, 10% or less, such as 5-15%, such as 8-12%, such as 10%, of the critical micelle concentration.

[0083] In an embodiment, the treatment step (A) is a pretreatment of the cells. Without wishing to be bound by theory, it is believed that treating cells with surfactants below the critical micelle concentration can reduce the strength of cell membranes and / or partially or completely eliminate the effects of detergents on mitochondria within cells.

[0084] Therefore, from the viewpoint of minimizing the effect of surfactants on mitochondria, at least in any step during or after the recovery of mitochondria from cells (e.g., each of steps (B) to (E)), the concentration of surfactant in the solution in contact with mitochondria may be lower than the critical micelle concentration, e.g., 10% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less of the critical micelle concentration, or lower, or lower than the detection limit. From the viewpoint of minimizing the effect of surfactants on mitochondria, it is preferred that surfactants should not be added to the solution in contact with mitochondria during and after the recovery of mitochondria from cells.

[0085] In an embodiment, the cell can take the form of the cell present in the tissue, or they can be separated from the tissue (e.g., unicellular) or be a colony thereof. The cell separated from the tissue can be a cultured cell or a unicellular cell or a colony thereof, which is obtained by treating the tissue or the cultured cell with an enzyme such as collagenase that makes the tissue or the cultured cell become a unicellular cell. If desired, before the enzyme such as collagenase is treated, the tissue can be shredded.

[0086] In embodiments, prior to recovering mitochondria from the surfactant-treated cells in (A), the surfactant may be removed from the solution to reduce the concentration of the surfactant in contact with the mitochondria or substantially reduce the surfactant in contact with the mitochondria.

[0087] In the removal step (B), the removal of the surfactant can be performed, for example, by replacing the buffer with a solution containing a lower or reduced concentration of the surfactant (preferably a solution without a surfactant) (e.g., a buffer) or adding the solution to the buffer. If the surfactant-treated cells are adherent cells, the surfactant-containing buffer can be removed by aspirating the solution, rinsing the cells in a solution containing a lower or reduced concentration of the surfactant (preferably a solution without a surfactant) (e.g., a buffer) if necessary, and adding a solution containing a lower or reduced concentration of the surfactant (preferably a solution without a surfactant) (e.g., a buffer). If the surfactant-treated cells are floating cells, the surfactant can be removed by centrifuging the cells, removing the supernatant, rinsing the cells in a solution containing a lower or reduced concentration of the surfactant (preferably a solution without a surfactant) (e.g., a buffer) if necessary, and adding a solution containing a lower or reduced concentration of the surfactant (preferably a solution without a surfactant) (e.g., a buffer).

[0088] Removal means at least reducing the concentration of the surfactant in the solution in contact with the mitochondria, including, for example, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% or less of the concentration of the surfactant, or below the detection limit in the solution in contact with the mitochondria. To ensure that the surfactant is removed from the solution, (B) may include washing the cells with a solution containing a lower or reduced concentration of the surfactant (preferably a solution without the surfactant) (e.g., a buffer).

[0089] In (B), in order to remove the surfactant from the solution, the solution added to or exchanged with the solution may preferably be a buffer, and may be the buffer described above in (A) (but a solution containing a lower concentration of surfactant, preferably a solution without surfactant or with an undetectable level of surfactant).

[0090] The cells treated in (A) have reduced plasma membrane strength, and only by incubating them in the solution, mitochondria are allowed to be released from the interior of the cells to the extracellular area. However, in the steps before (C), the amount of surfactant contacting the mitochondria is small, the effect of the surfactant on the mitochondria is limited, and thus the reduction of mitochondrial membrane strength is also limited, and / or the mitochondrial membrane remains intact.

[0091] In embodiments, the method comprises obtaining mitochondria released into the second solution simply by allowing the cells to sit in the second solution.

[0092] Therefore, in the present invention, the surfactant-treated cells can be incubated in a solution to release mitochondria from the interior of the cell to the extracellular region. In (C), the term "release" means that mitochondria leave the interior of the cell and arrive outside the region surrounded by the plasma membrane (e.g., on the solution side or on the outside of the cell).

[0093] The solution used for incubation in (C) ("second solution") can be a solution containing a lower concentration of a surfactant. In a preferred embodiment, the second solution is a surfactant-free solution or a solution with a negligible and / or undetectable amount of a surfactant. The solution used for incubation in (C) can be, for example, a buffer as described in (A) above, and can be a buffer with a lower concentration of a surfactant than described in (A) above (preferably a surfactant-free solution). The solution used in (C) can be a solution containing, for example, a buffer, an osmotic pressure modifier, and a divalent metal chelator and substantially free of a surfactant. When used herein, "substantially free of" is used in the sense of not excluding the presence of contamination by "substantially free of ingredients" in an amount that cannot be removed or detected.

[0094] In (C), the incubation can be performed for, for example, 1-30 minutes, such as 5-25 minutes, or for example, 5-20 minutes, such as 5-15 minutes, such as 10 minutes. The treatment of cells in (C) can be performed on ice or at room temperature or any temperature therebetween.

[0095] In (C), a physical stimulus can be added that does not mechanically disrupt the lipid bilayer of the mitochondria in order to enhance the recovery of mitochondria from the cells. Thus, for example, in (C), the incubation can be carried out under shaking or non-shaking conditions. In (C), the incubation can be carried out under stirring or non-stirring conditions. In (C), the surfactant treatment makes it easier for the cells to detach from the adhesion surface, so detaching the cells from the adhesion surface by gentle water flow as described above does not seem to have a negative impact on the polarizability. Alternatively, in (C), the incubation can be carried out to the extent that the cells do not become detached.

[0096] In (C), the mitochondria recovered in the solution can be used as an isolated mitochondrial population for a variety of applications. In an embodiment, the present disclosure provides a population of mitochondria produced by the methods provided herein, which are referred to herein as "Q" mitochondria. In an embodiment, the present disclosure provides a single mitochondria (i.e., a single Q) produced by the methods provided herein.

[0097] In embodiments, the method provided herein also includes (D) purifying the mitochondria recovered in the solution. Mitochondria can be separated from one or more other cellular components by centrifugation. For example, mitochondria can be purified as a supernatant by centrifuging the mitochondrial population recovered in (C) at a speed of 1500g or less, 1000g or less or 500g or less to precipitate out pollutants such as the detached cells contained in the mitochondrial population. The mitochondria can preferably be purified as a supernatant, for example, by centrifugation at 500g. Mitochondria can also be collected as a precipitate by further centrifuging the obtained supernatant (e.g., 8000g to 12000g) for enrichment, etc. The term "purified" used herein means that the mitochondria are separated from at least one other component in the solution by the operation.

[0098] The mitochondrial population obtained in (C) and / or (D) above can be used as an isolated mitochondrial population in various applications.

[0099] The method of the present invention may also include (E) freezing mitochondria. Freezing can be performed by gently suspending the mitochondria in a freezing buffer. The freezing buffer may be a buffer as described in (A), but does not include a surfactant, and may further include a cryoprotectant. Exemplary cryoprotectants are known in the art and include, but are not limited to, glycerol, sucrose, trehalose, dimethyl sulfoxide (DMSO), ethylene glycol, propylene glycol, diethylene glycol, triethylene glycol, glycerol-3-phosphate, proline, sorbitol, formamide, and polymers. Therefore, the mitochondria provided herein can be stored by freezing. In the method disclosed herein, if cryopreservation is not required, the mitochondria may not be frozen, for example, the mitochondria may be used when freshly isolated. In other embodiments, the mitochondria may be stored at 4°C ± 3°C or on ice. In an embodiment, the mitochondria provided herein produced by the method provided herein may be stored in liquid nitrogen, at about -80°C ± 3°C or lower, at about -20°C ± 3°C or lower, or at about 4°C ± 3°C. In embodiments, the mitochondria can be stored for days, weeks, or months, or longer, and retain the ability to function after thawing.

[0100] In embodiments, the methods provided herein also include methods for thawing mitochondria that have been isolated and subsequently frozen as provided herein. Methods for thawing mitochondria provided herein include thawing the mitochondria at about 20°C ± 3°C or lower, and thawing the mitochondria rapidly, for example, within about 5, about 4, about 3, about 2, or about 1 minute. In embodiments, rapid thawing of mitochondria produces mitochondria that retain the functional capabilities described herein.

[0101] In embodiments, the methods provided herein do not include methods for breaking cell membranes in a manner that breaks mitochondrial membranes during the entire process of collecting mitochondria from cells. For example, in the methods provided herein, cells are not broken by homogenization during the process of collecting mitochondria from cells. That is, in embodiments, the methods provided herein do not include homogenization; in embodiments, the methods include homogenization, but the homogenization is only performed to the extent that no bubbles are produced in the solution relative to the cells or tissues. In embodiments, the methods do not include freezing and thawing of cells either. Although repeated freezing and thawing of cells is suitable for breaking plasma membranes and recovering their contents, and can be used to recover mitochondria from cells, it is believed that freezing and thawing also breaks mitochondrial lipid bilayers because the membrane potential of the resulting mitochondria is not maintained (contrary to the methods of the present invention in which the mitochondrial membrane potential is maintained).

[0102] In embodiments, the methods of the present disclosure do not include other methods of disrupting cell membranes (e.g., sonication, treatment with strong water flow to the extent that the solution produces bubbles, or the extent that the solution foams) during the entire process of collecting mitochondria from cells. In embodiments, no process that may significantly cause physical, chemical or physiological damage to mitochondria is performed when performing the methods of the present disclosure, although freeze-thaw cycles may be applied to the storage of mitochondria. Therefore, the methods of the present invention can obtain mitochondria with minimal damage.

[0103] The methods of the present invention do not require one or more filtration steps in purifying mitochondria recovered from cells.

[0104] In embodiments, the methods provided herein gently separate mitochondria from the microtubule system without damaging the mitochondria while the mitochondria are still in the cell. During incubation, mitochondria that have become non-filamentous due to the detachment of microtubules from the mitochondrial surface are able to leave the cell through the surfactant-treated cell membrane. Thus, mitochondria obtained from cells by the disclosed methods are obtained without tearing or rupturing of the mitochondrial membrane or other damage to the mitochondrial structure. Thus, the isolated mitochondria and populations thereof provided herein are able to maintain function after isolation and are far more suitable for treating disease conditions than any previously described isolated mitochondria.

[0105] Thus, the methods provided herein differ from conventional methods of isolating mitochondria in important ways and provide isolated or obtained mitochondria having surprising and advantageous characteristics relative to mitochondria isolated by conventional methods or any other previously disclosed methods.

[0106] Mitochondrial population

[0107] On the one hand, the present disclosure provides a population of mitochondria that has been isolated from cells using the methods provided herein, resulting in a highly functional population of mitochondria. As described above, the new separation methods provided herein are interchangeably referred to as "DHF" methods or "iMIT" methods; mitochondria obtained by DHF or iMIT methods are referred to herein as "Q" mitochondria. The Q mitochondria avoid the fragmentation and membrane damage that occurs when mitochondria are isolated by conventional methods, and are therefore superior in structure and function to mitochondria isolated by conventional methods.

[0108] In embodiments, the disclosure provides a mitochondrial population isolated or obtained, wherein the population contains a high proportion of polarized mitochondria (i.e., the population has a high polarization rate). Therefore, the mitochondrial population provided herein comprises a high proportion of mitochondria with membrane potential. In embodiments, the disclosure provides a mitochondrial population, wherein a high proportion of mitochondria in the population have a complete inner membrane and outer membrane. In embodiments, the presence of a complete inner membrane and outer membrane can be determined by the functional activity of mitochondria such as membrane potential and polarization.

[0109] Therefore, the mitochondrial populations provided herein are superior to mitochondrial populations obtained from cells using conventional methods, such as the methods described above involving homogenization and / or freeze-thaw of cells and / or high concentrations of detergents or surfactants. For example, mitochondria isolated from cells by conventional methods are necessarily damaged by the isolation process and lose functional capacity. Therefore, there is provided in the present disclosure an isolated mitochondrial population having a higher polarization rate and / or a higher % polarization and / or a higher % of mitochondria with intact inner and outer membranes compared to mitochondrial populations obtained by conventional methods.

[0110] In an embodiment, the polarization rate of the isolated or obtained mitochondrial population can be, for example, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more or 85% or more.

[0111] In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or more of the isolated or obtained mitochondrial population is polarized when measured by a fluorescent indicator. In embodiments, the fluorescent indicator can be any fluorescent indicator known to those of ordinary skill in the art that is suitable for measuring mitochondrial membrane potential. In embodiments, the fluorescent indicator is selected from JC-1, TMRM and TMRE.

[0112] In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or more of the mitochondrial population isolated or obtained have complete inner and outer membranes. In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or more of the mitochondrial population isolated or obtained have densely folded cristae in the inner membrane. For example, in embodiments, the cristae structure of the Q mitochondria is similar to the cristae structure of mitochondria in cells, i.e., not yet isolated from cells. When used herein, the term "densely folded cristae" means that the mitochondria contain cristae that exist at high density, that is to say highly folded cristae. The density of cristae can be assessed using microscopy (e.g., transmission electron or optical microscopy, including confocal microscopy). In an embodiment, the ridge density in mitochondria can be measured by the number of ridge folds per square micron, which can be determined manually by counting the number of folds, and / or by an automated software program. In an embodiment, "high density of ridges", "densely folded ridges", etc. means at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8 or more ridges (i.e., ridge folds) per square micron. Alternatively or in addition, the ridge density in mitochondria can be measured by the ridge surface area per unit mitochondrial volume. Therefore, in an embodiment, "high density of ridges", "densely folded ridges", etc. means the ridge surface area (μm) per unit mitochondrial volume. 2 μm –3) is at least about 20, at least about 25, at least about 30, at least about 35, at least about 40 or more. Methods for determining cristae density are known in the art (see, for example, Segawa et al., "Quantification of cristae architecture reveals time dependent characteristics of individual mitochondria", Life Science Alliance, Vol. 3, No. 7, June 2020; and Nielsen et al., The Journal of Physiology 595.9 (2017) pp. 2839-47). In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more of the mitochondria in a population of mitochondria provided herein have at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, or more cristae per square micron, and / or have a cristae surface area per unit mitochondrial volume (μm) of at least about 20. 2 μm –3 ), at least about 25 μm 2 μm –3 , at least about 30μm 2 μm –3 , at least about 35 μm 2 μm –3 , at least about 40 μm 2 μm –3 Or higher. In embodiments, the average or representative cristae density of the isolated mitochondria provided herein is equal to and / or not significantly lower than the mitochondrial cristae density in the cell type from which the isolated mitochondria are obtained. In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or more of the mitochondria in the mitochondrial population provided herein exhibit a cristae density that is equal to and / or not significantly lower than the average or representative mitochondrial cristae density in the cell type from which the isolated mitochondria are obtained.

[0113] In embodiments, the isolated mitochondrial populations provided herein have a mitochondrial population that is capable of maintaining a stable mitochondrial structure even when exposed to high calcium (Ca 2+) environment. In embodiments, due to the isolation methods provided herein, the isolated mitochondrial population provided herein maintains functional capacity in the extracellular environment. In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or more of the isolated or obtained mitochondrial population maintains functional capacity in the extracellular environment. In embodiments, the extracellular environment comprises a total calcium concentration of about 6 mg / dL to about 14 mg / dL or about 8 mg / dL to about 12 mg / dL. In embodiments, the extracellular environment comprises a free / active calcium concentration of about 3 mg / dL to about 8 mg / dL or about 4 mg / dL to about 6 mg / dL. Thus, in embodiments, the Q mitochondria provided herein have the attractive feature of being isolated from the cellular environment with little or negligible damage, and retain the ability to function even when exposed to an extracellular environment, such as a calcium-rich environment, that would otherwise be expected to damage the mitochondria and / or significantly inhibit their functional capacity.

[0114] Without wishing to be limited by theory, in certain embodiments, the ability of the mitochondria separated or obtained herein to maintain functional capacity in an extracellular environment is partially or entirely due to the combination of tubulin with the voltage-dependent anion channel (VDAC) on the mitochondrial surface. For example, in embodiments, in the iMIT separation process provided herein, tubulin may be combined with all or a significant number of VDAC on the mitochondrial surface, so that mitochondria can maintain function even in a calcium-rich environment (e.g., an extracellular environment comprising about 3mg / dL to about 14mg / dL or more calcium). In embodiments, the combination of tubulin with VDAC on the mitochondrial surface of the separation can be determined by, for example, detecting the presence of tubulin at the mitochondrial surface by staining.

[0115] Without wishing to be limited by theory, in certain embodiments, the isolated Q mitochondria provided herein are able to maintain functional capabilities in an extracellular environment, in whole or in part due to the stripping of cholesterol, ergosterol and / or related molecules in the Q mitochondrial outer membrane during the iMIT separation. That is, due to the contact of a small amount of surfactant with the mitochondrial membrane during the separation procedure, cholesterol (which stabilizes the VDAC structure) may be stripped to a certain extent, resulting in the isolated mitochondria having VDAC on the surface that has lost some or all functions, so that the mitochondria become resistant to extracellular calcium concentrations (e.g., an extracellular environment containing about 3 mg / dL to about 14 mg / dL or more calcium). Therefore, in embodiments, the isolated mitochondria provided herein have very low levels of steroid concentrations in the mitochondrial membrane.

[0116] In an embodiment, the mitochondrial population isolated or obtained also exhibits reduced binding to mitochondrial associated membranes (MAMs) relative to mitochondria in cells and / or mitochondria isolated or obtained using conventional methods, such as homogenates involving cells and / or freeze-thaw of cells. In an embodiment, the reduced binding to MAMs is measured by the expression of glucose-regulated protein GRP75 at the mitochondrial surface.

[0117] In an embodiment, the shape of the isolated mitochondria is substantially non-filamentous. "Non-filamentous" can be used interchangeably with "non-network-like", etc., and means that the mitochondria do not exhibit the branching and network-like network of mitochondria present in cells (see, e.g., Fig. 7A Representative filamentous shapes of mitochondria in cells in the present invention). In embodiments, when viewed under a microscope, the mitochondria provided herein do not have a filamentous, network-like or branched structure, but are round, spherical, irregularly shaped and / or slightly elongated, or a mixture thereof. At lower magnifications, the isolated mitochondria are dot-like structures. In contrast, at lower magnifications, a highly elongated network or branched structure of mitochondria in cells can be seen. In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or more of the isolated or obtained mitochondrial population have a major diameter to minor diameter ratio of no more than 4:1, no more than 3.5:1 or no more than 3:1. Without wishing to be limited by theory, the shape of the mitochondria isolated by the methods provided herein is derived from the gentle removal of the connection of the motor protein to the microtubules while the mitochondria are still in the cell before separation. That is, once mitochondria are no longer tethered to the cell's microtubules, they lose the highly elongated branched / networked shape they had while inside the cell and instead develop the non-filamentous shape described herein.

[0118] In embodiments, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the isolated mitochondria in the mitochondrial population provided herein have a length shorter than twice the hydrodynamic diameter of the mitochondria. In embodiments, the hydrodynamic diameter is about 1 μm, and at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the isolated mitochondria in the mitochondrial population provided herein have a length of 2 μm or less, 1.9 μm or less, 1.8 μm or less, 1.7 μm or less, 1.6 μm or less, 1.5 μm or less, 1.4 μm or less or 1.3 μm or less in the length of the main axis. In embodiments, the hydrodynamic diameter is measured by dynamic light scattering (DLS). In embodiments, the hydrodynamic diameter is the median diameter D 50 .

[0119] Typically, in cells, the shape of mitochondria is highly elongated, or takes the form of filamentous branching structures as described above. Non-filamentous and non-elongated mitochondria are usually only present in cells where drp1-dependent fission or drp1-dependent fission is occurring. For this mitochondrial fission process, interaction with the endoplasmic reticulum leads to the initial contraction of mitochondria. Drp1 protein is summoned to mitochondria and assembled on its surface, leading to further contraction. DYN2 is summoned to carry out the final membrane rupture stage. The resulting mitochondria may generally have a spherical shape. In cells, such spherical mitochondria may maintain a spherical shape for a limited period of time before becoming elongated or forming a more typical branching structure. In contrast, mitochondria separated using the iMIT method have a non-filamentous shape without undergoing Drp1-mediated fission. In addition, the shape of mitochondria separated by conventional methods, such as methods involving cell homogenization, is non-filamentous, mostly round or spherical, because they have been damaged and torn off from the microtubules that originally kept them in an elongated shape in the cell. In contrast to mitochondria isolated in this manner, mitochondria isolated by the iMIT method provided herein have not undergone damaging removal from microtubules and are not undergoing drp1-mediated fission. Therefore, the mitochondria of the present disclosure are different from both native mitochondria in cells and mitochondria isolated by more conventional methods. For example, in an embodiment, the shape of the mitochondria obtained by the iMIT method provided herein is substantially non-filamentous, and at the same time exhibits a highly functional state (e.g., polarization), intact and inner and outer membrane structures including densely folded cristae, and at the same time is not undergoing drp1 fission.

[0120] In an embodiment, the Q mitochondria provided herein, when contacted with a cell or a cell population, exhibit the surprising characteristics of co-localization with the endogenous mitochondria in the one or more cells. Compared with mitochondria isolated by conventional methods, the Q mitochondria are co-localized with endogenous mitochondria at a much higher degree. In an embodiment, the Q mitochondria provided herein, when contacted with a cell or a cell population, fuse with the endogenous mitochondria in the one or more cells. The fusion of the isolated Q mitochondria is significantly different from and superior to the mitochondria isolated by conventional methods. In an embodiment, the mitochondria retain this ability even after storage. Therefore, in an embodiment, the Q mitochondria provided herein are at least superior to conventionally isolated mitochondria in that they are more efficiently co-localized and / or fused with endogenous mitochondria in cells, and therefore exhibit superior clinical effects when used to treat any disease or disorder, such as a disease or disorder described herein. This may indicate that the Q mitochondria provided herein have a more robust and nearly complete outer membrane compared to conventionally isolated mitochondria.

[0121] In an embodiment, the present disclosure provides a mitochondrial population isolated or obtained by the method provided herein. For example, the present disclosure provides a mitochondrial population isolated or obtained by a method comprising steps (A) to (C) of the iMIT method described above. In an embodiment, the present disclosure provides a mitochondrial population isolated or obtained by a method comprising steps (A) to (E) described above.

[0122] According to the present disclosure, a composition comprising an isolated mitochondrial population of the present invention is provided. According to the present disclosure, a mitochondrial preparation comprising an isolated mitochondrial population of the present invention is provided. The composition comprising the isolated mitochondrial population of the present invention may also include a buffer. The mitochondrial preparation comprising the isolated mitochondrial population of the present invention is pharmaceutically acceptable and may also include other pharmaceutically acceptable components such as excipients. The isolated mitochondrial population of the present disclosure or a composition or mitochondrial preparation containing it can be obtained during the separation process, and cell sorting such as fluorescence activated cell sorting (FACS) performed by flow cytometry is not used. Therefore, the isolated mitochondrial population of the present invention or a composition or mitochondrial preparation containing it does not contain fluorescent dyes and fluorescent probes (as well as non-fluorescent mitochondrial stains and probes). In an embodiment, the composition is a pharmaceutical composition.

[0123] Detection of mitochondrial membrane potential

[0124] Whether mitochondria have membrane potential (whether polarized) can be determined by detecting mitochondrial membrane potential. Mitochondrial membrane potential can be detected using indicators such as fluorescent indicators. Fluorescent indicators for detecting mitochondrial membrane potential include JC-1, tetramethylrhodamine methyl ester (TMRM) and tetramethylrhodamine ethyl ester (TMRE). JC-1 accumulates in mitochondria, detects mitochondrial membrane potential and changes from green to red. TMRM and TMRE accumulate in mitochondria, detect mitochondrial membrane potential and produce red light.

[0125] When detecting mitochondrial membrane potential, depolarized mitochondria can be used as negative control. Mitochondria can be depolarized by mitochondrial depolarizing agents. Mitochondria depolarizing agents include, for example, carbonyl cyanide-m-chlorophenylhydrazone (CCCP). For example, by incubating the mitochondrial membrane potential (or the fluorescence intensity when using a fluorescent indicator) after depolarization for 1 hour at room temperature in the presence of 5 μM CCCP, it can be used as a negative control, and the mitochondria with a potential higher than the membrane potential of the negative control (or the fluorescence intensity when using a fluorescent indicator) can be determined as mitochondria with membrane potential. The fluorescence intensity of the analyte and the negative control can be determined by excluding the influence of the fluorescence from the background (for example, as a ratio or difference with the background fluorescence intensity). When the mitochondrial membrane potential of the negative control is variable, the mitochondria with a membrane potential higher than 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more or 99% or more of the negative control can be determined as mitochondria with membrane potential. In this way, the mitochondrial membrane potential in the mitochondrial population can be detected. In the method disclosed herein, no other steps leading to loss of mitochondrial membrane potential can be performed in the detection of mitochondrial membrane potential.

[0126] The mitochondrial polarization rate is the ratio (%) of the number of mitochondria with membrane potential to the total number of mitochondria. The mitochondrial polarization rate can be obtained from, for example, a certain area (e.g., 100 μm) of a substrate plate such as glass on which mitochondria are fixed. 2 Up to 10,000 μm 2 ) and the number of mitochondria with membrane potential in the region. Mitochondria can be counted, for example, using an optical microscope.

[0127] Treatment

[0128] In one aspect, the present disclosure provides methods for treating diseases or disorders associated with mitochondrial dysfunction or that would otherwise benefit from supplementing healthy, functioning mitochondria.

[0129] In embodiments, the disease or disorder suitable for treatment using the Q mitochondria provided herein is a genetic disease or disorder, an ischemia-related disease or disorder, a neurodegenerative disease or disorder, cancer, a cardiovascular disease or disorder, an autoimmune disease, an inflammatory disease, a fibrotic disease, a disease or disorder of aging, or a disease associated with birth complications.

[0130] Exemplary ischemia-related diseases and disorders include cerebral ischemia-reperfusion, hypoxic-ischemic encephalopathy, acute coronary syndrome, myocardial infarction, liver ischemia-reperfusion injury, ischemic compartment syndrome, vascular occlusion, wound healing (e.g., acute trauma or chronic trauma; cuts, lacerations, crush injuries, burns (e.g., chemical, heat or flame, wind or sunlight burns), or wounds caused by medical or surgical interventions), spinal cord injury, sickle cell disease, and transplant organ reperfusion injury. In embodiments, the Q mitochondria can treat, prevent, improve and / or ameliorate clinical conditions caused by ischemia-reperfusion injury. In embodiments, the Q mitochondria can increase ejection fraction (EF), inhibit cardiac hypertrophy, and / or treat, prevent, improve and / or ameliorate fibrosis following ischemia-reperfusion injury.

[0131] Exemplary autoimmune and / or inflammatory and / or fibrotic diseases and disorders include acute respiratory distress syndrome (ARDS), celiac disease, vasculitis, lupus, chronic obstructive pulmonary disease (COPD), irritable bowel disease, inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease), multiple sclerosis, atherosclerosis, arthritis, and psoriasis.

[0132] Exemplary cancers include, e.g., breast cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, testicular cancer, lung cancer, hepatocellular carcinoma, kidney cancer, bladder cancer, gastric cancer, colorectal cancer, pancreatic cancer, esophageal cancer, melanoma, lymphoma, leukemia, and blastoma (e.g., neuroblastoma).

[0133] Other diseases and disorders that can be treated by administering the Q mitochondria provided herein include diabetes (type I and II), metabolic diseases (e.g., hyperglycemia, hypoglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, metabolic syndrome, syndrome X, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, dyslipidemia, hypertriglyceridemia, kidney disease, ketoacidosis, thrombotic disease, nephropathy, diabetic neuropathy, fatty liver, nonalcoholic fatty liver disease and steatohepatitis), eye disorders associated with mitochondrial dysfunction (e.g., glaucoma, diabetic retinopathy or age-related macular degeneration), hearing loss, leukemia associated with therapeutic agents. In some embodiments, the disease or disorder is mitochondrial toxicity, cardiotoxicity associated with chemotherapy or other therapeutic agents, mitochondrial dysfunction (e.g., mitochondrial myopathy, diabetes and deafness (DAD) syndrome, Barth syndrome, Leber hereditary optic neuropathy (LHON), Leigh syndrome, NARP (neuropathy, ataxia, retinitis pigmentosa, and ptosis syndrome), myoneurogenic gastrointestinal encephalopathy (MNGIE), MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome, myoclonic epilepsy with ruffled red fibers (MERRF) syndrome, Kearns-Sayre syndrome, and mitochondrial DNA depletion syndrome), or migraine. In embodiments, the disease or disorder is pre-eclampsia or intrauterine growth restriction (IUGR).

[0134] In embodiments, the present disclosure provides methods for treating aging and aging-related disorders, the methods comprising administering to a subject in need thereof a Q mitochondria provided herein. Normal aging and aging-related disorders can be treated with the compositions and methods provided herein. Aging-related disorders include neurodegenerative disorders, cardiovascular disorders, hypertension, obesity, osteoporosis, cancer, and type II diabetes.

[0135] Exemplary neurodegenerative diseases and disorders include, for example, dementia, Friedreich's ataxia, amyotrophic lateral sclerosis, mitochondrial myopathy, MELAS (encephalopathy, lactic acidosis, stroke), myoclonic epilepsy with ruffy red fibers (MERFF), epilepsy, Parkinson's disease, Alzheimer's disease, or Huntington's disease. Exemplary neuropsychiatric disorders include bipolar disorder, schizophrenia, depression, addiction, anxiety, attention deficit disorder, personality disorder, autism, and Asperger's disease.

[0136] Exemplary cardiovascular diseases include coronary heart disease, myocardial infarction, atherosclerosis, hypertension, cardiac arrest, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, congestive heart failure, arrhythmia, stroke, deep vein thrombosis, and pulmonary embolism.

[0137] In one aspect, the disclosure provides methods for improving mitochondrial function in a cell, in a tissue of a subject, in an organ, in an egg cell, or in an embryo. In embodiments, the organ is a heart, lung, kidney, brain, skeletal muscle, skin tissue, facial muscle, bone marrow tissue, or white adipose tissue. In embodiments, the organ is a transplanted organ. In embodiments, the cell is a transplanted cell. In embodiments, the tissue is a transplanted tissue such as a transplanted bone marrow tissue.

[0138] On the one hand, the present disclosure provides a method for detecting mitochondrial dysfunction. In an embodiment, the method includes detecting a biomarker for mitochondrial dysfunction. In an embodiment, the present disclosure provides a method for detecting mitochondrial dysfunction, and if mitochondrial dysfunction is detected in a subject, treating the subject with the Q mitochondria provided herein. In an exemplary embodiment, the biomarker for mitochondrial dysfunction may be heteroplasmy, peripheral mitochondrial count, mitochondrial DNA deletion or duplication, and / or DNA methylation level. In an embodiment, the biomarker may be blood levels of growth differentiation factor 15 (GDF15), apelin, humanin, and / or fibroblast growth factor 21 (FGF21).

[0139] In an embodiment, the Q mitochondria provided herein are administered systemically (e.g., intranasally, intramuscularly, subcutaneously, intra-arterially, intratracheally, by inhalation, intrapulmonary or intravenously) or topically. In an embodiment, the mitochondria are administered to the subject in a pharmaceutically acceptable carrier. In an embodiment, the mitochondria are administered to the subject in combination with one or more other agents and / or other therapies designed to treat the disease or disorder. In an embodiment, the mitochondria are isogenic, allogenic or xenogeneic mitochondria.

[0140] The present disclosure also provides uses of Q mitochondria for the manufacture of a medicament for treating the diseases and disorders provided herein. The present disclosure also provides Q mitochondria for use in any of the methods provided herein.

[0141] The present disclosure also provides a kit for treating the diseases and disorders provided herein. In an embodiment, the kit comprises a population of Q mitochondria provided herein. In an embodiment, the kit further comprises instructions for administering the Q mitochondria to a subject. In an embodiment, the present disclosure also provides a kit for isolating Q mitochondria, such as a kit for performing an iMIT isolation method. In an embodiment, the kit comprises a surfactant, a buffer, and instructions for use for isolating mitochondria from cells by the iMIT method provided herein.

[0142] All documents and similar materials cited in this application, including but not limited to patents, patent applications, articles, books, papers and Internet web pages, are expressly incorporated herein by reference in their entirety for any purpose. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the various embodiments described herein belong. When the definition of a term in an incorporated reference appears to differ from the definition provided in this teaching, the definition provided in this teaching shall prevail.

[0143] Example

[0144] Example 1. Comparison of the detergent-free and homogenization (DHF) method ("iMIT") with conventional methods

[0145] Studies were conducted to compare conventional separation methods involving homogenization and / or high concentrations of surfactants with the detergent-free and homogenization methods provided herein. Mitochondria isolated by the iMIT method are referred to herein as "Q" mitochondria. Mitochondria isolated by homogenization and detergent methods are referred to herein as H-mitochondria or H-mito and D-mitochondria or D-mito, respectively.

[0146] The cells used in this study were human-derived HeLa cells (RCB3680) purchased from the RIKEN cell bank. The culture medium used for the culture was passaged once or twice a week in MEM + 10% FBS. For the DHF method, the following steps were performed.

[0147] 1) The cells were cultured in a 100 mm diameter culture dish and confirmed to be 80% confluent.

[0148] 2) The culture medium was discarded, and the cells were washed twice with 3 mL of separation buffer (10 mM Tris-HCl, 250 mM sucrose, 0.5 mM EGTA, pH 7.4).

[0149] 3) Add 3 mL of separation buffer containing 30 μM digitonin and allow the dish to stand at room temperature for 3 minutes.

[0150] 30μM is about 1 / 10 of the critical micelle concentration (cmc) of digitonin (2,3) .

[0151] 4) Wash the inside of the culture dish twice with 3 mL of separation buffer.

[0152] 5) Add 3 mL of separation buffer and allow the dish to stand at 4°C for 10 minutes.

[0153] 6) Detach the cells by gentle pipetting using a micropipette.

[0154] 7) The suspension containing the detached cells and mitochondria is then transferred to a 15 mL centrifuge tube, centrifuged at 500 × g, 4°C for 10 minutes and 2 mL of supernatant is collected to obtain an isolated mitochondrial population. At this stage, the isolated mitochondrial population may or may not be frozen by the following method.

[0155] 8) When freezing, glycerol is added to a freezing buffer (10 mM Tris-HCl, 225 mM mannitol, 75 mM sucrose, 0.5 mM EGTA, pH 7.4) to make a glycerol concentration of 10%, but no separation buffer is used, and a frozen material of isolated mitochondria (an isolated mitochondrial population in a frozen state or a composition containing it) is obtained by freezing with liquid nitrogen.

[0156] A second isolation method was performed to test the use of higher concentrations of surfactant (at or above the critical micelle concentration) to isolate mitochondria. The following steps were performed.

[0157] 1) The cells were cultured in a 100 mm diameter culture dish and confirmed to be 80% confluent.

[0158] 2) Discard the culture medium and wash the cells twice with 3 mL of separation buffer.

[0159] 3) Digitonin dissolved in 3 mL of separation buffer was added at a concentration of 400 μM (critical micelle concentration), and the dish was allowed to stand at room temperature for 3 minutes.

[0160] 4) Detach the cells by gentle pipetting using a micropipette.

[0161] 5) Transfer 3 mL of the suspension to a 15 mL centrifuge tube, centrifuge at 500 × g, 4°C for 10 min and collect 2 mL of the supernatant to obtain the isolated mitochondrial population.

[0162] 6) When freezing, glycerol was added to the freezing buffer so that the glycerol concentration was 10% to suspend it, and it was frozen in liquid nitrogen to obtain a frozen material of isolated mitochondria.

[0163] The third separation method was performed using conventional homogenization methods and the following steps.

[0164] 1) The cells were cultured in a 100 mm diameter culture dish and confirmed to be 80% confluent.

[0165] 2) Discard the culture medium and wash the cells twice with 2 mL of separation buffer.

[0166] 3) Add 3 mL of separation buffer and detach the cells using a cell spatula.

[0167] 4) The suspension of the detached cells was homogenized in a Potter-type glass Teflon (registered trademark) homogenizer while the suspension was cooled in ice. This operation was repeated five times.

[0168] 5) The homogenate was transferred to a 15 mL centrifuge tube, centrifuged at 500 × g, 4°C for 10 min and 2 mL of supernatant was collected to obtain isolated mitochondrial populations.

[0169] 6) When freezing, glycerol was added to the freezing buffer so that the glycerol concentration was 10% to suspend it, and it was frozen in liquid nitrogen to obtain a frozen material of isolated mitochondria.

[0170] Mitochondria isolated by each of the above methods were adsorbed onto a glass-based culture dish, and the membrane potential of individual mitochondria was observed using a fluorescence microscope. The procedure was as follows:

[0171] 1) The suspension containing isolated mitochondria (300 μL) was spread on the glass surface of a glass-based culture dish and allowed to stand on ice for 1 hour to fix the isolated mitochondria on the glass surface. Subsequently, 2 mL of 1M KOH was added to the glass-based culture dish (35 mm) to wash the glass surface.

[0172] 2) Wash the culture dish twice with 2 mL of Milli-Q water.

[0173] 3) Wash with 2 mL of ethanol.

[0174] 4) Wash the culture dish twice with 2 mL of Milli-Q water.

[0175] 5) Wash the dish twice with 2 mL of separation buffer.

[0176] The isolated mitochondria were subjected to particle size analysis, zeta potential analysis and polydispersity (PDI) analysis using a potentiometric analyzer (Nanosize Nano-ZS, Malvern) according to the manufacturer's manual. Depolarization of mitochondria and staining of mitochondria with membrane potential sensitive dyes were performed as follows.

[0177] 1) Wash mitochondria adsorbed to glass-based culture dishes with 2 mL of isolation buffer.

[0178] 2) Add 2 mL of separation buffer containing 5 μM CCCP and allow the dish to stand at room temperature for 1 hour.

[0179] 3) The buffer was replaced with 2700 μL of TMRE staining buffer (10 mM Tris-HCl, 250 mM sucrose, 10 nM TMRE, 0.33 mg / mL BSA) containing 5 μM CCCP, and the dish was allowed to stand in the dark at room temperature for 10 minutes.

[0180] 4) A total of 56 μL of malic acid and glutamic acid were added so that the concentration of each was 5 mM. Fluorescence observation was performed at room temperature for 5 minutes.

[0181] Isolated mitochondria were stained with a membrane potential sensitive dye as follows.

[0182] 1) Wash mitochondria adsorbed to glass-based culture dishes with 2 mL of isolation buffer.

[0183] 2) The buffer was replaced with 2700 μL TMRE staining buffer (10 mM Tris-HCl, 250 mM sucrose, 10 nM TMRE, 0.33 mg / mL BSA), and the dish was allowed to stand in the dark at room temperature for 10 minutes.

[0184] 3) A total of 56 μL of malic acid and glutamic acid were added so that the concentration of each was 5 mM. Fluorescence observation was performed at room temperature for 5 minutes.

[0185] The images were observed using an Olympus fluorescence microscope IX70 and a cooled CCD camera (Sensicam QE, PCO AG; Kelheim, Germany) (6.45 μm / pixel) under the following conditions:

[0186] Objective lens: ×40, NA0.9

[0187] Light source: Halogen lamp

[0188] Absorption filter: center wavelength 546nm, bandpass 10-nm

[0189] CCD camera: Bin: 2×2

[0190] Exposure time: 1 second

[0191] Use the same instrument as for transmitted light to observe the same field of view. The conditions that differ from transmitted light are as follows:

[0192] Light source: Xenon lamp

[0193] Excitation filter: through a 520-550nm bandpass filter

[0194] Fluorescence filter: A sharp-cut filter that passes light of 580nm or higher wavelengths

[0195] For fluorescence image analysis, a 0.94 μm 2 The area of ​​​​the mitochondria was determined, and the average value of the fluorescence intensity in the area was obtained. The ratio of this value to the background fluorescence intensity was determined as the ratio of the fluorescence intensity of each mitochondria. The fluorescence intensity ratio was calculated by rounding to the second decimal place.

[0196] The distribution of fluorescence intensity ratios was obtained from the fluorescence intensity ratios in depolarized mitochondria determined as described in Section 2.4.7, and the threshold value of the fluorescence intensity ratio representing depolarized mitochondria was determined. The results are shown in Figure 1A In. Figure 1A As shown in , in the presence of 5 μM CCCP, more than 97% of mitochondria exhibited a fluorescence intensity ratio of 1.2 or less. Therefore, we used a fluorescence intensity ratio of 1.2 as a threshold to determine whether mitochondria were polarized.

[0197] The proportion of polarized mitochondria of mitochondria isolated by the DHF method, the homogenization method, and the surfactant method (n=130 to 150, respectively) was determined. The results are shown in Table 1. The polarization rate is, for example, Figure 1B The transmitted light image on the left shows a diameter of 0.5-1.5 μm and Figure 1B The right panel shows the percentage of black spots with a TMRE fluorescence intensity ratio greater than the threshold of 1.2. The mitochondria were examined before freezing.

[0198] [Table 1] Polarization rate of mitochondria obtained by different methods

[0199] Methods for obtaining mitochondria Polarizability DHF method (iMIT) 90% Homogenization method 38% Surfactant method (cmc concentration) 38%

[0200] Figure 2A The TMRE fluorescence of the Q mitochondrial population (iMIT method) compared to the homogenate method mitochondrial population is shown. Tables 1 and 2 and Figure 2B It was confirmed that when the number of cells was equal during isolation and the protein content of the obtained mitochondrial fraction was equal, the mitochondria isolated by the iMIT method showed a statistically significant increase in the percentage of TMRE-positive mitochondria compared with the conventional method (*p<0.05, Figure 2B in the figure below). Figure 2C It shows that almost all mitochondria obtained by the iMIT method are TMRE+. 10 black dots randomly selected from the bright field image were compared with TMRE positive staining, indicating that 90% of mitochondria are TMRE positive. Figure 2D It was shown that mitochondria isolated by iMIT retain double membranes (inner and outer membranes) and cristae structure.

[0201] [Table 2] Protein content and number of isolated cells obtained by the DHF method compared with the homogenization method

[0202]

[0203] The Q mitochondria obtained by the iMIT method were observed using stimulated emission depletion (STED) microscopy and compared with those obtained by the conventional homogenization method (H mito) or the conventional detergent method (D mito). Figure 2E ). The outer membrane was stained green (immunofluorescence of Tom20), while the inner membrane was stained red using Mitotracker Red. As can be seen in Figure 2E As seen in, Q mitochondria have complete inner membrane and outer membrane, while H mitos have far less detectable inner membrane or complete outer membrane, and D mitos have even less detectable inner membrane or outer membrane. In addition, in H mitos, some inner membranes are shown to protrude from the outer membrane, indicating that the outer membrane is physically damaged during separation. In D mitos, many small fragments from the outer membrane are detected, and some outer membranes do not have inner membranes inside the outer membrane, which indicates that the surfactant used in the separation process dissolves the outer membrane and the inner membrane to chemically destroy the separated mitochondria. The ratio of mitochondria with membrane potential obtained from this study, the ratio of mitochondria with complete outer membrane, the diameter of mitochondria along the long diameter and the ratio of the major diameter to the minor diameter are quantitatively provided in Table 3 below. Protein content (mitochondria obtained from HeLa cells--1 150Φ culture dish, 12 million cells) was also measured. Membrane potential is measured in mitochondria isolated from HUVEC cells. The ratio, diameter and the ratio of the major diameter to the minor diameter of the complete outer membrane are measured in mitochondria isolated from HeLa cells.

[0204] [Table 3] Ratio of membrane potential, ratio and diameter of intact outer membrane

[0205]

[0206] The results of these studies confirm that the iMIT method of the present invention is suitable for preparing mitochondria that can maintain structural integrity and exhibit polarization. The studies also show that the mitochondria obtained by the iMIT method of the present invention have a higher proportion of mitochondria that can exhibit polarization (polarization rate) compared to conventional mitochondrial preparation methods (homogenate and high surfactant methods). The studies also confirm that the mitochondria separated by the iMIT method have a non-filamentous shape and are generally less round or spherical than H and D mitochondria. The studies reveal that pre-treating cells with surfactants at concentrations below the critical micelle concentration is sufficient to recover mitochondria from the interior of the cells. In addition, the studies show that the mitochondria separated by the iMIT method are fundamentally different from the mitochondria separated by conventional methods and are functionally superior.

[0207] The size distribution and zeta potential of mitochondria isolated by the iMIT method were measured. The size distribution and zeta potential of the sample before freezing (i.e., Q mitochondria freshly isolated by the iMIT method) are shown in Figure 3AIn. Figure 3A As shown in , mitochondria isolated by the iMIT method showed monodispersity with a size (particle size) of 1034 nm. This result indicates that there is less contamination with nuclear DNA and cell-derived debris, and the majority of the recovered material is mitochondria.

[0208] Then, the size distribution and zeta potential of the samples obtained by the iMIT method after freezing and subsequent thawing are shown in Figure 3B Freezing was performed by suspending the mitochondria in a freezing buffer and then freezing the sample with liquid nitrogen. Sample transportation to and from liquid nitrogen was performed on dry ice. Thawing was performed by holding the mitochondrial vial under running tap water while rotating the vial, allowing it to thaw within 3 minutes. Figure 3B As shown in , the size (particle size) of mitochondria isolated by the iMIT method was 1171 nm even after freezing and thawing.

[0209] In addition, the size distribution and zeta potential of mitochondria isolated by the iMIT method (with the difference that the centrifugation was performed at 1000×g instead of 500×g) were determined and the results are shown in Figure 3C After the mitochondria thus isolated were frozen and thawed, the size (particle size) of the sample was 858.5 nm.

[0210] In all the above samples, the zeta (ζ) potential was good (between -22.4 mV and 031.0 mV).

[0211] right Figure 3A Samples and Figure 3B The samples were stained with TMRE and the staining superimposed on the bright field image (merged) is shown in Figure 3D The results showed that the isolated mitochondria showed a high polarization rate before and after freezing and thawing.

[0212] A study was conducted to evaluate the use of surfactants other than digitonin. Saponin (concentration: about 40 μM, which is about 1 / 15 of the CMC) was used instead of digitonin to separate mitochondria from cells in a manner similar to that described above. The CMC of saponin is believed to be 538-646 μM (Komatsu et al., J.Oleo.Sci.54:265-270 (2002)). A good mitochondrial population was obtained by this method, with characteristics similar to those of the mitochondria obtained using digitonin.

[0213] Approximately 0.1 g, 1.2 g and 1.2 g of heart, liver and skeletal muscle obtained from mice were minced and treated with collagenase (concentration: 0.2 wt%) at 37°C for 30 min. In this way, mitochondria were isolated from monocytic cells using digitonin below the CMC using the iMIT method described above. The size, polydispersity and zeta potential of the isolated mitochondria were measured by dynamic light scattering. The results are shown in Figure 4 In Figure 4 As shown in , mitochondria isolated from liver and heart showed good zeta potential. Mitochondria isolated from skeletal muscle also showed good zeta potential (i.e., about -15 mV) and had a size distribution of about 100 nm to about 2,000 nm. These results indicate that mitochondria can be directly isolated from tissue samples by the iMIT method. Specifically, mitochondria obtained from liver showed the lowest zeta potential and were considered to be advantageous in these embodiments.

[0214] like Figure 5A and 5B As shown in , the activity of mitochondria isolated by the iMIT method was evaluated. After isolation, mitochondria were incubated at room temperature in 20 nM TMRE, 1 mM KH 2 PO 4 , 0.5 mM ADP-K, 0.33 mg / ml BSA, 0.5 M EGTA, 10 mM Tris, 110 mM sucrose and 70 mM KCl were incubated for 10 minutes. The TMRE fluorescence of 10 mitochondria at t=0 was averaged and normalized to 1. 1 mM malate was added between 0 and 1 min. 1 μM oligomycin was added between 5 and 6 min. Figure 5A Shown are changes in TMRE fluorescence in individual mitochondria. Figure 5B Images showing a typical time course of fluorescence images of TMRE in a single mitochondria. The time interval between images is 1 min.

[0215] Example 2. Colocalization of Q mitochondria with endogenous mitochondria in recipient cells

[0216] A study was conducted to determine whether mitochondria isolated by the iMIT method (Q) could colocalize with mitochondria in recipient cells. Mitochondria were isolated from cardiac progenitor cells by the iMIT method and stained with Mito Tracker (red). Endogenous mitochondria in recipient LHON fibroblasts were labeled green. Exogenous Mito tracker mitochondria were contacted with the recipient cells and confocal microscopy images were acquired. Representative images are provided at Fig. 6A and showed that isolated mitochondria moved into cells and colocalized with recipient mitochondria after overnight. Figure 6BA comparison of co-localization between mitochondria isolated using conventional homogenization methods and mitochondria isolated using the iMIT method provided herein is provided. Figure 6B The figure above shows that several mitochondria isolated by conventional methods appear to move into the cell. However, far more mitochondria isolated by the iMIT method move into the cell, and only the iMIT method mitochondria co-localize with the recipient cell mitochondria to form filamentous, network-like and / or reticular structures ( Figure 6B , figure below).

[0217] Example 3. Shape of functional isolated mitochondria

[0218] A study was conducted to determine whether mitochondria isolated by the iMIT method provided herein are undergoing drp1-mediated fission. Typically, mitochondria in most cell types are long, filamentous, and form a network or reticular structure; any mitochondria within a cell that do not have a long filamentous and reticular shape are typically non-filamentous because they are undergoing drp1-mediated fission.

[0219] In the study, the drp1 inhibitor Mdivi1 was added to the cells. The mitochondria in the cells showed both network-like and filamentous shapes ( Fig. 7A In contrast, mitochondria in cells treated with the iMIT method in the absence or presence of Mdivi1 (0 or 10 μM Mdivi1; Figure 7B ) In both cases, the shape is non-filamentous. Therefore, the non-filamentous shape of iMIT begins while the mitochondria are still in the cell and is independent of drp1-mediated fission. Figure 7C Mitochondria after iMIT separation are shown, and it is demonstrated that they retain a non-filamentous shape. Thus, the study demonstrates that the non-filamentous shape of mitochondria isolated by the iMIT method provided herein is independent of drp1 fission. That is, the Q mitochondria differ from mitochondria present in cells at least in that they are non-filamentous, but are not undergoing drp1-dependent fission.

[0220] Example 4. Polarizability under Ca2+ conditions

[0221] A study was conducted to evaluate the function of Q mitochondria under high calcium conditions. Mitochondria were isolated from cells by the iMIT method, detergent method or homogenization method. Each of the three mitochondrial populations was divided into two subpopulations. The first subpopulation was incubated in Tris-HCl-sucrose-EGTA buffer containing BSA and 10nM TMRE as a control. The second subpopulation was incubated in a Tris-HCl-sucrose-EGTA buffer containing 200mg / mL CaCl 2 The cells were incubated in DMEM with BSA and 10 nM TMRE for 10 min.

[0222] The results of the study showed that mitochondria isolated by the iMIT method (Q) showed polarization under Ca2+ conditions, while mitochondria isolated by the detergent method (D-mito) or the homogenate method (H-mito) did not show polarization under Ca2+ conditions ( Figure 8 ).exist Figure 8 In the middle row of Figure 1, a zoomed-in view of the D-mito micrograph shows the presence of many mitochondria in the sample, but the TMRE image does not show any TMRE+ mitochondria. Figure 8 Many TMRE+Q mitochondria can be seen in the upper row of . Thus, the study shows that Q mitochondria retain the ability to function even when exposed to a high Ca2+ environment.

[0223] Further studies were performed using calcein fluorescence to detect holes in the mitochondrial membrane. Q mitochondria were isolated from HUVEC cells by the iMIT method and adsorbed on glass-based culture dishes. TMRE and calcein fluorescence in individual mitochondria were observed using fluorescence microscopy. Fluorescence changes after the indicated treatments were continuously observed in the same microscopic field.

[0224] Q mitochondria were incubated with 1 μM Calcein-AM in isolation buffer containing 5 mM malate and 5 mM glutamate for 10 min at room temperature and washed gently with isolation buffer. Fig.9A The figure above shows the calcein fluorescence in Q when 1 mL of separation buffer was used ( Fig.9A ). Fig.9A The figure below shows the calcein fluorescence in Q after adding 4 mL HBS (10 mM HEPES, 120 mM NaCl, 4 mM KCl, 0.5 mM MgSO4, 1 mM NaH2PO4, 4 mM NaHCO3, 25 mM glucose, 1.2 mM CaCl2, 0.1% bovine serum albumin, pH 7.4). HBS was added gently to the edge of the culture dish. Therefore, the addition of calcium did not change the calcein fluorescence, confirming that Q mitochondria isolated by the iMIT method maintain membrane integrity in a Ca2+-rich environment.

[0225] The studies further demonstrated that Q mitochondria maintained membrane potential in a Ca2+-rich environment, as measured by TMRE fluorescence ( Fig. 9B ). Q was incubated with 10 nM TMRE in separation buffer containing 5 mM malate and 5 mM glutamate for 10 min and washed gently with separation buffer. Fig. 9B The upper panel shows TMRE fluorescence in Q using 1 mL of separation buffer. Q was adsorbed in the center of a glass-based culture dish containing 1 mL of separation buffer. Fig. 9BThe figure below shows TMRE fluorescence when 4 mL of HBS was added. HBS was gently added to the edge of the dish. TMRE fluorescence was maintained after the addition of HBS.

[0226] Interestingly, when mitochondria were physically disrupted by applying physical stimulation such as pipetting (agitation) outside the presence of Ca2+, mitochondria lost calcein fluorescence ( Fig. 10A ). Q was incubated with 1 μM calcein-AM in separation buffer containing 5 mM malate and 5 mM glutamate for 10 min at room temperature and gently washed with separation buffer. Agitation of Q by pipetting (10-15 times) reduced calcein fluorescence, as in Fig. 10A The calcein fluorescence after addition of 0.96 mM Ca2+ is shown in the right picture in the middle row. To add Ca2+, 4 mL of HBS containing 5 mM malate and 5 mM glutamate was gently added to the edge of the dish. The Q was agitated again with 10-15 pipettings in the presence of Ca2+, and the calcein fluorescence after addition of Ca2+ and agitation is shown in the left picture in the middle row. The calcein fluorescence after 10 minutes is shown in Fig. 10A In the figure below. In addition, Fig. 10B TMRE staining is shown, showing that despite the effect of stirring (pipetting 10-5 times) on the mitochondrial membrane, the membrane potential (as measured by TMRE staining) is maintained; however, after the stirred mitochondria are exposed to a Ca2+ environment (0.96mM Ca2+), the mitochondria lose their membrane potential. Q was incubated at room temperature for 10 minutes in 20nM TMRE in a separation buffer containing 5mM malate and 5mM glutamate. The fluorescence value is the ratio of TMRE fluorescence in the mitochondria to the background (upper left figure, Fig. 10B ). After 10-15 times of agitation, the TMRE fluorescence is shown in Fig. 10B In the upper right panel of the figure, the TMRE fluorescence in Q after the addition of Ca2+ is shown in Fig. 10B In the lower right figure of the figure, 4 mL of HBS containing 5 mM malate and 5 mM glutamate was gently added to the edge of the culture dish. In the presence of Ca2+, after 10-15 pipetting agitations, TMRE fluorescence in Q was shown to be Fig. 10BIn the lower left figure. The results of the study show that although mitochondria are resistant to Ca2+ environments, after receiving physical stimulation or fragmentation, the mitochondria may lose Ca2+ tolerance. Therefore, without wishing to be limited by theory, the results show that the combination of physical destruction (e.g., shaking or stirring) of mitochondria and / or a rich Ca2+ environment with physical destruction such as shaking or stirring may cause mitochondria to lose membrane integrity and / or membrane potential. Without wishing to be limited by theory, the results show that if the mitochondria separated by the iMIT method are in contact with or stored in a Ca2+ environment, then, for example, before being used for therapeutic treatment, they should be operated with minimal destruction.

[0227] Example 5. GRP27 content

[0228] A study was conducted to compare the glucose-regulated protein 75 (GRP75) content of mitochondria isolated by the iMIT method provided herein with that of mitochondria isolated by a detergent method or a homogenate method. Mitochondria were isolated from HeLa cells by each of the three methods, and western blotted to detect GRP75 protein. Cytochrome oxidase was used as a protein content control. The results of the study showed that mitochondria isolated by the iMIT method provided herein had much lower GRP75 content ( Fig.11 and Table 4).

[0229] [Table 4] Comparison of GRP75 protein content

[0230]

[0231] Example 6. In vivo effects in a myocardial infarction model with 4-week follow-up

[0232] Using a myocardial infarction (ischemia-reperfusion of the coronary arteries) model in rats, the effects and safety of local injection of Q mitochondria (isolated by the iMIT method provided herein) on improvement of cardiac function and prevention of cardiac remodeling were evaluated.

[0233] The test article "Q" mitochondrial population was prepared using HUVEC (immortalized human umbilical vein endothelial cell line, HUEhT-1) by the iMIT method provided herein. After separation, the mitochondrial population was cryopreserved in liquid nitrogen for 1-2 weeks before use. The prepared population was thawed and prepared according to the internal procedures used at the research site. Male Slc:Wister rats aged 11-12 weeks were used in the study, and myocardial infarction was induced using a 30-minute surgical occlusion of the left anterior descending artery (LAD). Animals were grouped by a stratified random allocation method so that the average body weight between the groups was almost equal.

[0234] One minute before reperfusion, Q mitochondria were locally injected into 3 sites near the infarct area on the left ventricular myocardial tissue using a needle (26-30G), and the dose at each site was 0.23 μg / (low dose) or 11.5 μg / (high dose) in 30 μL. PBS (-) was used as a negative control. Mitochondria isolated using a conventional mitochondrial isolation kit (89874, ThermoScientific) were used as a comparator at a high dose (11.5 μg / ) and administered in the same manner as Q mitochondria. The sham group underwent open surgery, but was not treated in other aspects. Ten animals were assigned to each group. After administration, body weight was measured weekly, and echocardiography was performed before administration, at the 2nd week, and at the 4th week. Blood was collected and the heart and lungs were separated at the 4th week, and the weight of the heart, left and right atria and ventricles, and lungs were weighed. Histopathological examination was performed using the isolated left ventricle. In addition, the size of the myocardial infarction site and the relative area of ​​cardiac fibrosis were determined. The general condition of the animals was observed daily. All animals were sacrificed 4 weeks after administration, and organ weights were measured and histopathological examinations of the heart and lung were performed. Fig.12 A schematic diagram of the study design is provided.

[0235] The ischemia-reperfusion (IR) model animals prepared in this study showed left ventricular tissue remodeling (increased LVIDs and LVIDs and decreased LVAWd), abnormal left ventricular systolic function (decreased EF and %FS), a significant increase in relative organ weight, and the formation of myocardial infarction lesions and cardiac fibrosis. In addition, histopathological examination revealed cardiac regenerative necrosis, inflammatory cell infiltration, interstitial edema, fibrosis and hemorrhage. One of the 10 animals in the control group died on the 8th day after the preparation of the myocardial infarction model (8 days after administration). This event was judged as a pathological death related to myocardial infarction.

[0236] There was no significant difference in body weight in the Q group compared with the PBS control and the conventional mitochondrial control group.

[0237] Echocardiography data are presented in Table 5. There were no significant differences in the Q group compared to the PBS control and the conventional mitochondrial control group for LVIDd (left ventricular internal dimension at diastole: the internal dimension when the heart is dilated), LVAWd (left ventricular anterior wall at diastole: the thickness of the anterior wall when the heart is dilated), or LVPWd (left ventricular posterior wall at diastole: the thickness of the posterior wall when the heart is dilated).

[0238] For LVIDs (systolic left ventricular internal dimensions: the internal dimensions of the heart when it contracts), high dose Q showed significant reductions compared to both PBS and conventional mitochondrial controls (p<0.05 vs. PBS control, p<0.01 vs. conventional mitochondrial control) (Table 5).

[0239] When evaluating ejection fraction (EF; an index of the total volume of blood ejected in a single cardiac contraction), significant improvements were observed in both Q groups relative to the PBS control and conventional mitochondrial control at weeks 2 and 4 (p<0.01) (Table 5). The data are also shown in Fig.13 middle.

[0240] For fractional shortening (FS; index of left ventricular contractility), significant increases in FS were also observed for both Q groups relative to PBS control and conventional mitochondria at weeks 2 and 4 (p<0.01) (Table 5).

[0241] [Table 5] Echocardiography results

[0242]

[0243]

[0244] Each value represents the mean ± SE

[0245] Each number in brackets represents the number of animals.

[0246] QN-01: Q (test object)

[0247] LVIDd: left ventricular internal dimension at diastole, LVIDs: left ventricular internal dimension at systole, LVAWd: left ventricular anterior wall at diastole, LVPWd: left ventricular posterior wall at diastole, EF: ejection fraction, %FS: % fractional shortening

[0248] ##: Significantly different from the sham operation group, P<0.01 (compared with control-1 or control-2, Student's t-test or Aspin-Welch t-test).

[0249] * and **: There are significant differences between Control-1 and QN-01, P < 0.05 and P < 0.01, respectively (Dunnett's test).

[0250] $$: There was a significant difference between control-2 and QN-01, P < 0.01 (Dunnett's test).

[0251] Organ weights are presented in Table 6. There were no significant differences in total heart weight between groups or total relative heart weight (ratio of organ weight to total body weight) between groups. However, a significant inhibitory effect of left atrial weight was observed in the high-dose Q group compared with the conventional mitochondrial control group (p<0.01). The relative weight of the left atrium was also significantly suppressed in the high-dose Q group compared with the PBS control (p<0.05) and conventional mitochondrial control (p<0.01) groups. The relative weight of the right atrium was significantly reduced in the high-dose Q group compared with the conventional mitochondrial control group (p<0.05). Compared with the conventional mitochondrial control group, lung weight was significantly lower in the high-dose Q (p<0.01) and low-dose Q (p<0.05) groups, and the relative lung weight was significantly suppressed in the high-dose Q group compared with the PBS control (p<0.05) and mitochondrial control (p<0.01) groups, and the relative lung weight was significantly suppressed in the low-dose Q group compared with the conventional mitochondrial control (p<0.05).

[0252] [Table 6] Organ weight

[0253]

[0254]

[0255] Each value represents the mean ± SE

[0256] QN-01: Q (test object)

[0257] BW: body weight, HW: heart weight, RAW: right atrium weight, LAW: left atrium weight, RVW: right ventricle weight, LVW: left ventricle weight, LW: lung weight

[0258] # and ##: significantly different from the sham-operated group, P < 0.05 and P < 0.01, respectively (compared to control-1 or control-2, Student's t-test or Aspin-Welcht-test).

[0259] *: There is a significant difference between control-1 and QN-01, P<0.05 (Dunnett's test).

[0260] $ and $$: There were significant differences between control-2 and QN-01, P < 0.05 and P < 0.01, respectively (Dunnett's test).

[0261] There were no significant differences in myocardial infarct size, but the relative area of ​​myocardial fibrosis was significantly smaller in high-dose Q compared with conventional mitochondrial controls (p<0.05) (Table 7).

[0262] [Table 7] Fibrosis area

[0263]

[0264] Each value represents the mean ± SE

[0265] QN-01: Q (test object)

[0266] ##: Significant difference from the sham operation group, P<0.01 (compared to control-1 or control-2, Aspin-Welcht-test).

[0267] There was no significant difference between Control-1 and QN-01 (Dunnett's test).

[0268] $: There was a significant difference between Control-2 and QN-01, P<0.05 (Dunnett's test).

[0269] In histopathological studies, no abnormalities were found in samples obtained from 10 animals in the sham group. In all other groups, mild to moderate myocardial regenerative necrosis, mild to moderate interstitial edema, and mild to moderate fibrosis were reported.

[0270] In conclusion, the high-dose (11.5 μg) Q group showed statistically significant improvements in left ventricular tissue remodeling (inhibition of LVIDs increase) and left ventricular systolic function (EF and %FS) compared with the negative control and comparator (conventional isolated mitochondria) groups with statistically significant differences (p<0.01) ( Fig.13 ). A significant reduction in relative organ weights (heart and lung) and the area of ​​cardiac fibrosis was also observed in the Q group. In histopathological examination, the extent of fibrotic and interstitial edema changes was lower in the Q group than that observed in the negative control and comparator groups. Statistical significance was also detected in the low-dose (0.23 μg) Q group in terms of improvement in left ventricular systolic function (EF, %FS) and the extent of interstitial edema compared with the negative control and comparator groups (p<0.01)( Fig.13 ).

[0271] Taken together, based on the studies presented herein, local injection of Q mitochondria at a dose of 0.23 μg / rat or 11.5 μg / rat in IR model rats prevented left ventricular enlargement and improved left ventricular contractile function based on echocardiography examination. In addition, Q mitochondria altered the increase in relative organ weight of the heart and lung and cardiac fibrosis formation according to the results of histopathological examination. The effect of Q mitochondria was higher at a dose of 11.5 μg.

[0272] Example 7. Myocardial infarction model with 7-day analysis

[0273] A second study was conducted in a rat model of myocardial infarction (ischemia-reperfusion of the coronary arteries) to further evaluate the ability of Q mitochondria to provide protection against ischemia-reperfusion injury. Test article "Q" was prepared by the iMIT method using GFP-HUVEC (immortalized human umbilical vein endothelial cell line labeled with green fluorescent protein) and cryopreserved in liquid nitrogen for approximately 4 weeks before being used in this study. In this example, the Q mitochondria are referred to as "QN-01".

[0274] The animals were divided into groups by a stratified random assignment method so that the mean body weights were almost equal between the groups. In the sham group (0.23 μg labeled QN-01, using a sham procedure - open surgery, but without IR preparation) and the control group (PBS), two animals were assigned for observations on day 1, day 3, and day 7. In the labeled QN-01 group (0.23 μg labeled QN-01 test group), three animals were assigned for the same observations.

[0275] Animals were prepared by 30-minute occlusion of the left anterior descending artery (LAD) in rats followed by reperfusion. As in the study described in Example 6 above, QN-01 was administered at a dose of 0.23 μg into 3 sites near the LV in myocardial tissue 1 min before reperfusion (29 min after occlusion).

[0276] Body weight was measured and echocardiography was performed 1, 3, or 7 days after dosing. In addition, blood was collected, the heart and lungs were isolated, and the weights of the heart, right and left atria and ventricles, and lungs were measured 1, 3, or 7 days after dosing. All animals underwent organ weight measurement and histopathological examination of the heart and lungs. Samples obtained from study animals were examined microscopically for the presence of GFP and tested by immunohistochemical staining using an anti-human mitochondrial antibody as the primary antibody to study the cellular uptake of labeled QN-01. A schematic diagram of the study design is provided at Fig.14 middle.

[0277] No deaths were reported in this study, and all animals were monitored until planned necropsy. In echocardiography, the negative control group showed decreased EF (ejection fraction), decreased %FS (fractional shortening), and increased LVIDs at 1, 3, and 7 days after drug administration (PBS administration), and increased LVIDs were observed at 3 and 7 days after drug administration. The Q group showed superior effects in improving left ventricular systolic function (EF and %FS) compared with the negative control group, although statistical analysis was not planned in this study due to the limited number of animals ( Fig.15 The increase of LVIDd and LVID was also suppressed compared with the control (Table 9).

[0278] [Table 8] Effects of QN-01 on echocardiographic parameters LPWD, EF and %FS

[0279]

[0280] -: No data

[0281] QN-01: Q (test object)

[0282] LVPWd: left ventricular posterior wall in diastole, EF: ejection fraction, %FS: % fractional shortening

[0283] [Table 9] Effects of QN-01 on echocardiographic parameters LVIDd, LVIDs and LVAWd

[0284]

[0285] -: No data

[0286] QN-01: Q (test object)

[0287] LVIDd: left ventricular internal dimension in diastole

[0288] LIVDs: left ventricular internal dimensions during systole

[0289] LVAWd: left ventricular anterior wall in diastole

[0290] In histopathology, there was no difference in the intensity of fluorescein staining between the dosing groups, including the negative control group, and Q was not detected in any sample collected on days 1, 3, or 7. Similarly, in the immunohistochemical staining assay, none of the samples tested were positive for the detection of Q. In histopathological evaluation, the degree of myocardial degeneration and necrosis and inflammatory cell infiltration were slightly reduced in the Q group compared to the negative control on day 7 (Table 10). Plasma samples collected from all animals were analyzed for cytokines and chemokines using a Multiplex assay system (Luminex 17Plex*Assay, R&D System).

[0291] [Table 10] Histopathological findings on day 7. Grade of changes: - = normal; + = mild; ++ = moderate; +++ = severe

[0292]

[0293] In conclusion, echocardiography examination revealed that in the QN-01 group, the decrease in EF and %FS was suppressed at 1, 3, and 7 days after administration compared with the PBS control group. In addition, the increase in LVIDd and LVIDs was also suppressed. In the histopathological examination 7 days after administration, there was a trend of slightly increasing myocardial regenerative necrosis and inflammatory cell infiltration found in the control group relative to the QN-01 group.

[0294] Thus, the study demonstrated that local injection of QN-01 in myocardial infarction model rats prepared by 30 min infarction prevented left ventricular enlargement and improved left ventricular systolic function. In addition, QN-01 altered the extent of myocardial regenerative necrosis and inflammatory cell infiltration in the heart.

[0295] References

[0296] 1.Shibata et al., Biochem.Biophys.Res.Commun.(2015)463,563-8.doi:10.1016 / j.brc.2015.05.095.

[0297] 2.Baker, et al., Eur.J.Transl.Myol.2015,25,35–48.

[0298] 3.Stetsenko and Gustov.Crystal.2017,7:197. https: / / doi.org / 10.3390 / cryst 7070197

[0299] 4. Shin B, Cowan DB, Emani SM, Del Nido PJ, McCully JD. Mitochondrial Transplantation in Myocardial Ischemia and Reperfusion Injury. Adv. Exp. Med. Biol. 2017;982:595–619.

[0300] 5. Emani SM, Piekarski BL, Harrild D, Del Nido PJ, McCully JD. Autologous mitochondrial transfer for dysfunction after ischemia-reperfusion injection. 2. J. Thorac. Cardiovascular. Surg. 2017; 154(1): 286–289.

[0301] 6. Bertero E, Mack C, O'Rourke B. Mitochondrial Transplantation in Humans: "Magical" cure or cause for concern? J. Clin. Invest. 2018 Dec 3;128(12):5191-5194.

[0302] 7. Segawa et al., Quantification of cristae architecture reveals time dependent characteristics of individual mitochondria, Life Science Alliance, Vol. 3, No. 7, June 2020

[0303] 8. Nielsen et al., The Journal of Physiology 595.9 (2017) pp. 2839-47

Claims

1. A method for isolating mitochondria from cells, the method comprising: (i) treating the cells in a first solution containing a surfactant, wherein the concentration of the surfactant in the first solution is lower than the critical micelle concentration of the surfactant, wherein the first solution is a solution containing a surfactant and a separation buffer, wherein the separation buffer consists of 10 mM Tris-HCl, 250 mM sucrose, 0.5 mM EGTA, and has a pH of 7.4, and the surfactant is digitonin, and the concentration of digitonin in the first solution is 30 μM to 40 μM, (ii) removing the surfactant to form a second solution, (iii) incubating the cells in the second solution, and (iv) recovering isolated mitochondria from the second solution; and wherein the method is not homogenization.

2. The method according to claim 1, wherein: (a) the first solution further comprises a buffer containing one or more of a tonicity agent, an osmotic pressure modifier, or a chelating agent; (b) treating the cells in the first solution comprises incubating the cells in the first solution at room temperature for 2 minutes to 30 minutes; and (c) removing the surfactant comprises reducing the surfactant in the solution to less than 1% of the concentration of the surfactant in the first solution; and (d) removing the surfactant comprises washing the cells with a buffer; and (e) incubating with the second solution comprises incubating the cells in the second solution at 4° C. for 5 minutes to 30 minutes.

3. An isolated mitochondrial population obtained by the method according to claim 1 or 2, wherein: (i) at least 80% of the mitochondria in the population have intact inner and outer membranes, (ii) at least 80% of the mitochondria in the population are polarized as measured by a fluorescent indicator, and / or (iii) at least 80% of the mitochondria in the population maintain functional capacity in the extracellular environment, wherein the mitochondria are isolated or derived from cells contacted with a surfactant at a concentration below the critical micelle concentration (CMC) of the surfactant.

4. The isolated mitochondrial population according to claim 3, wherein the functional capacity in the extracellular environment of (iii) is measured by a fluorescent indicator of membrane potential.

5. The isolated mitochondrial population of claim 3, wherein the extracellular environment of (iii) comprises a total calcium concentration of 8 to 12 mg / dL.

6. The isolated mitochondrial population of claim 3, wherein at least 80% of the mitochondria in the population are not undergoing dynamin-related protein 1 (drp1)-dependent fission.

7. The isolated mitochondrial population of claim 3, wherein at least 80% of the mitochondria in the population have a non-filamentous shape.

8. The isolated mitochondrial population of claim 3, wherein the mitochondria exhibit reduced binding to mitochondrial associated membranes (MAMs) as measured by expression of glucose regulated protein 75 (GRP75).

9. The isolated mitochondrial population according to claim 4, wherein the fluorescent indicator is selected from JC-1, tetramethylrhodamine methyl ester (TMRM) and tetramethylrhodamine ethyl ester (TMRE).

10. The isolated mitochondrial population of claim 3, wherein the polydispersity index (PDI) of the population is between 0.2 and 0.

8.

11. The isolated mitochondrial population of claim 3, wherein the polydispersity index (PDI) of the population is between 0.2 and 0.

3.

12. The isolated mitochondrial population of claim 3, wherein the zeta potential of the mitochondrial population is between -15 mV and -40 mV.

13. The isolated mitochondrial population according to claim 3, wherein after contacting the isolated mitochondrial population with a cell population, the isolated mitochondria are capable of co-localizing and / or fusing with endogenous mitochondria in the cells after storage at 4°C for at least 12 hours.

14. The isolated mitochondrial population according to any one of claims 3 to 13, wherein the mitochondria are capable of co-localizing with endogenous mitochondria after the population has been subjected to one or more freeze-thaw cycles.

15. A composition comprising the isolated mitochondrial population according to any one of claims 3-14.

16. A preparation comprising the composition according to claim 15 and a pharmaceutically acceptable carrier.

17. Use of the isolated mitochondrial population according to any one of claims 3 to 14, or the composition according to claim 15, or the preparation according to claim 16 in the preparation of a medicament for treating a disease or disorder, wherein cells of a subject in need are contacted with the isolated mitochondrial population, the composition, or the preparation, wherein the disease or disorder is myocardial infarction.

18. The use according to claim 17, wherein the isolated population of mitochondria or the composition or the preparation is administered to the subject by intravenous, intraarterial, intratracheal, subcutaneous, intramuscular, inhalation or intrapulmonary administration.

Citation Information

Patent Citations

  • Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity

    CN103299193A

  • Compositions and methods for treatment of mitochondrial diseases and for differentiation of cells to neurons

    CN105008515A

  • Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction

    CN108290889A

  • Screening assay using mitochondrial calcium

    JP2003519505A

  • Screening assays using intramitochondrial calcium

    US20010046664A1